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ABSTRACT 
The survival and proliferation of metastases is a consequence of the pre-metastatic 
niche (PMN) evolution, an abnormal, tumor growth-favoring microenvironment 
devoid of cancer cells. Among tumor derived secreted factors, extracellular vesicles 
(EVs) are key players in PMN establishment and facilitate organotropic metastasis. 
Compared to normal melanocytes, melanoma cells produce a large quantity of EVs, 
that can be detected in the plasma of melanoma patients. For this reason, a full 
characterization of secreted vesicles subpopulations and of their cargo is necessary to 
understand how EVs affect PMN formation. 
In this study, we demonstrated for the first time that EVs secreted by isogenic 
primary tumor and metastatic melanoma cell lines are quantitatively and 
qualitatively different, suggesting that diverse EVs subpopulations characterize 
metastatic progression. We also set a deep quantitative proteomics protocol to analyze 
the proteome of these cells and of their EVs and soluble secreted factors. WNT5A was 
found as an important component of primary tumor secreted EVs; on the contrary, we 
observed a specific APOE and Fibronectin sorting to EVs in in metastasis versus 
primary tumor cell. Finally, we observed that increased levels of RAB27A protein in 
metastatic cells do not correlate with an increased EVs secretion. Our preliminary 
results demonstrate that EVs secreted by RAB27A-KD cells maintain cancer cells 
clonogenic ability and that low levels of RAB27A expression correlate with higher 
cells motility. These findings suggest a paracrine activity of a RAB27A -independent 
EVs subpopulation in tumor-PMN communication to promote cancer progression. 
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INTRODUCTION 
1. The pre-metastatic niche 
1.1 Pre-Metastatic Niche explains metastases formation 
Metastases are characterized by a unique microenvironment, composed of neoplastic 
cells, tumor-associated cells, endothelial cells, inflammatory cells, extracellular 
matrix and soluble factors.  
The secondary organs involved in this process do not passively accept cancer cells, but 
are selectively modified by the primary tumor through the Pre-Metastatic Niche 
(PMN) establishment {Peinado H., et al., 2017}. Indeed, the primary tumor, co-
evolving with its microenvironment, secrete factors that reach the bone marrow to 
educate and mobilize Bone Marrow Derived Cells (BMDCs). The same factors are also 
delivered to the secondary organs, where they induce vascular leakiness, alterations 
of resident cells (such as fibroblasts) and recruit the mobilized BMDCs promoting 
processes including Extracellular Matrix (ECM) remodeling, immunosuppression, 
inflammation, and vascular hyper permeability {Sceneay J., et al., 2013}. By 
preparing the microenvironment of secondary organs in advance, the PMN formation 
allow the colonization and the outgrowth of Circulating Tumor Cells (CTCs), without 
needing for the primary tumor cells to acquire extra mutations before starting the 
colonization of the metastatic site {Psaila B. and Lyden D., 2009} (Figure 1). 
14 
 
 
Figure 1: Model of the pre-metastatic niche formation.  
During primary tumor development, secreted factors attract BMDCs and stromal cells to tumor microenvironment (1). 
At the same time, they are delivered both to the bone marrow, promoting BMDCs  education and mobilization (2), and 
to the secondary organ, to recruit BMDCs and CTCs to pre-metastatic sites (3). (Adapted from Peinado H., et al., 2011) 
So far, the interaction between CTCs and the microenvironment in secondary organs 
has been only hypothesized {Paget S., 1889; Fidler I.J. and Nicolson G.L., 1976}. The 
PMN discovery demonstrated for the first time that the primary tumor preconditions 
specific organ sites for future metastases before CTCs arrival, representing an 
abnormal, tumor growth-favoring microenvironment devoid of cancer cells. 
The existence of PMNs in tissue samples was observed in patients with colorectal, 
prostate, breast, thyroid, bladder, gastric and renal cell carcinomas {Sleeman J.P., 
2015}, and there are evidences of PMN establishment also in preclinical models of 
melanoma {Peinado H., et al., 2012} and acute myeloid leukemia {Kumar B., et al., 
2017}. 
1.2 Pre-metastatic niches formation is a stepwise process 
The initial steps of PMN development are clot formation and vascular disruption. 
Clots are a source of inflammatory signals able to reduce both shear stress and 
interstitial flow, providing docking sites for CTCs {Gay L.J. and Feldi-Habermann B., 
2011}. On the other hand, the loss of vascular integrity is achieved by a combination 
of focal adhesion kinase activation, to disrupt endothelial cell–cell contacts, and of 
enhanced microvessels permeabilization through tumor-secreted factors such as 
15 
 
vascular endothelial growth factor A and angiopoietin-like 4 {Hiratsuka S., et al., 
2011}. Additionally, BMDCs are recruited by local increase in cytokines and their 
adhesion is promoted by the deposition of ECM, in particular by the accumulation of 
Fibronectin (FN) and by the crosslinking of Collagen I via lysyl oxidase. ECM 
remodeling is also promoted by distant and local secretion of Matrix 
Metalloproteinases (MMPs), which also contributes to the early vascular disruption 
step {Erler J.T., et al., 2009}. The future infiltration of metastasis-initiating cells is 
also sustained by the WNT signaling via transforming growth factor-β dependent 
production of proteins such as periostin {Kudo A., 2011}. Inflammatory responses 
within PMNs is mediated by the S100 family of proteins, that are crucial in 
intercellular crosstalk between tumor cells and stromal cells during PMN formation. 
These proteins have both autocrine and paracrine effects on proliferation, 
differentiation, apoptosis, Ca2+ homeostasis, migration and invasion because they 
activate cell surface receptors, G-protein-coupled receptors, scavenger receptors, 
heparan sulfate proteoglycans and N-glycans {Lukanidin E. and Sleeman J.P., 2012}. 
The metastatic niche is therefore the combined result of BMDC recruitment, ECM 
remodelling and inflammation, and the survival and proliferation of cancer cells is a 
consequence of PMN evolution. 
1.3 Tumor secreted factors are key players of  the pre-metastatic niche establishment 
Tumor derived factors are molecules directly secreted from the cell in the 
extracellular space or Extracellular Vesicles (EVs) (better described in section 2).  
Those factors exert crucial effects on PMN establishment and facilitate organotropic 
metastasis; indeed, Kaplan and colleagues demonstrated that in mice pretreated with 
melanoma cells-conditioned medium it is possible to detect metastases of Lewis lung 
carcinoma cells in the spleen, the kidney, the oviduct and the intestine, even if those 
cells are expected to colonize only the lung {Kaplan R.N., et al., 2005}. Subsequently, 
other studies have demonstrated that a pre-conditioned microenvironment is a key 
determinant of organ-specific metastasis, showing that tumor cell-intrinsic metastatic 
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properties are not enough for metastatic colonization. To date, the understanding of 
which characteristics distinguish PMNs in each organ is still a matter of debate. 
The majority of the studies on PMNs have been performed on orthotopic and 
transgenic mouse models of lung metastases, that are one of the most frequent sites of 
metastasis both in humans and mice {Francia G., et al., 2011}. Furthermore, PMNs 
were identified in sentinel lymph nodes, where it was demonstrated that tumor cells 
encounter immune cells and interact with them to modulate immune response {Jung 
T., et al., 2009} and in bones with osteolytic lesions {Cox T.R., et al., 2015}. Moreover, 
exosomes (a specific class of extracellular vesicles; better described in section 2) were 
demonstrated to be biomarkers and functional contributors to liver PMNs {Costa-
Silva B., et al., 2015}. Finally, the presence of PMNs in the brain is still under 
investigation {Peinado H., et al., 2017}.  
Table 1 summarizes the known molecules that determine organotropic metastasis. 
Molecule Target Tumor type 
Integrin α6 
Laminin-expressing epithelial 
cells and fibroblasts in lung 
Lung-metastatic breast cancer, 
osteosarcoma and 
rhabdomyosarcoma 
Integrin αv 
Fibronectin-expressing Kupffer 
cells in liver 
Colorectal cancer, pancreatic 
cancer, gastric cancer and 
uveal melanoma 
Integrin β3 Endothelial cell in brain 
Brain-metastatic breast cancer 
and brain-metastatic 
melanoma 
Integrin β4 
Laminin-expressing epithelial 
cells and fibroblasts in lung 
Lung-metastatic breast cancer, 
osteosarcoma and 
rhabdomyosarcoma 
Integrin β5 
Fibronectin-expressing Kupffer 
cells in liver 
Colorectal cancer, pancreatic 
cancer, gastric cancer and 
uveal melanoma 
Integrin β1 
Endothelial cell and collagen I− 
and VCAM1-expressing cells in 
bone marrow 
Prostate cancer 
IL-1β and TNF Endothelial cell in liver Colorectal and hepatic cancer 
17 
 
Integrin α2 
Endothelial cell and collagen I-
expressing cells in bone marrow  
Prostate cancer 
Integrin α3 Laminin-expressing cells in lung Breast cancer 
Integrin α4 
Endothelial cell and VCAM1-
expressing cells in bone marrow 
Myeloma 
MIF Kupffer cells in liver Pancreatic cancer 
miR-105 Endothelial cell in brain Breast cancer 
FUT3 Liver Colorectal cancer 
SELPLG Endothelial cells in bone marrow Prostate cancer 
Integrin β3 
Endothelial cell and OPN-, FN- 
and VN-expressing cells in bone 
marrow 
Breast and prostate cancer 
Integrin αvβ3 Lung Osteosarcoma 
CDH11 Osteoblast in bone Ewing sarcoma 
CXCR4 
SDF1-expressing cells in 
lymphnodes, bone marrow, lung 
and liver 
Breast cancer 
FN 
DPP4-expressing endothelial cells 
in lung 
Breast cancer 
FUT4  Endothelial cells in brain Non-small-cell lung cancer 
GLG1  Endothelial cells in bone marrow Prostate cancer 
SPARC, MMP1 and 
IL13Rα2 
Lung Breast cancer 
CTGF, FGF5, IL-11, 
MMP1 and ADAMTS1 
Osteoblasts, osteoclasts and 
endothelial cells in bone 
Breast cancer 
Table 1: Known secreted molecules that determine organotropic metastasis.  
Abbreviations: ADAMTS1, a disintegrin and metalloproteinase with thrombospondin motifs 1; CDH11, cadherin 11; 
CTGF, connective tissue growth factor; CXCR4, C-X-C motif chemokine receptor 4; DPP4, dipeptidyl peptidase 4; FGF5, 
fibroblast growth factor 5; FN, fibronectin; FUT, fucosyltransferase; GLG1, Golgi apparatus protein 1; IL, interleukin; 
IL13Rα2, interleukin-13 receptor-α2; MIF, macrophage migration inhibitory factor; miR, microRNA; MMP1, matrix 
metalloproteinase 1; OPN, osteopontin; SDF1, stromal cell-derived factor 1; SELPLG, P-selectin glycoprotein ligand 1; 
SPARC, secreted acidic and rich in cysteine; TNF, tumor necrosis factor; VCAM1, vascular cell adhesion molecule 1; VN, 
vitronectin. (Adapted from Peinado H., et al., 2017) 
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1.4 Targeting PMN will improve cancer therapy  
The discovery of the PMN allowed a better understanding of metastatic progression 
and, at the same time, indicated new challenges in finding a cure for cancer. Indeed, 
the majority of current treatments for metastatic diseases only help to prolong 
patient survival, while a complete eradication of the tumor is still to be achieved. 
The cause of  therapy ineffectiveness could be the failure of drugs to reach the PMN. 
Indeed, since it is clear that the PMN maturation requires a continuous incoming of 
primary tumor-derived factors {Deng J., et al., 2012}, the complete removal of the 
primary tumor at early stage by surgery is currently the first and the most effective 
treatment to prevent metastasis formation. However, cancer cells that have reached 
the PMNs before the intervention could continue secreting PMN-promoting factors 
even if the primary tumor has been removed, supporting the formation of further 
metastases. For this reason, targeting pre-metastatic niches to reduce or prevent 
metastatic disease is highly desirable in cancer therapy {Sceneay J., et al., 2013}. 
One of the major challenge in PMNs targeting is the fact that it is difficult to predict 
if and how a novel therapy could impact PMN formation: for example, it has been 
shown that the removal of hematopoietic stem cells from their niches alter the bone 
marrow microenvironment, allowing cancer cells to engraft {Scadden D.T., et al., 
2014}. It was also hypothesized that both specific targeting of PMN components and 
the use of angiogenesis inhibitors to stabilize PMN vasculature could reduce 
metastasis, but the efficacy of this approach has yet to be determined due to the lack 
of clinical trials to test any drug in pre-metastatic patients. Moreover, both in patients 
and in preclinical models there are technical limitations in detecting PMNs with 
current technologies. Indeed, the detection of hyper permeable regions, hypoxic and 
inflammatory areas, ECM alterations or BMDC recruitment at pre-metastatic stages 
needs to be improved with more sensitive approaches, such as the labeling of specific 
factors that are up-regulated in PMNs, as it was done detecting melanoma exosomes 
in lymph nodes {Hu L., et al., 2014}. 
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Finally, biomarkers discovery and 3D modeling of organ-specific niches to enable a 
systematic dissection of its cellular and extracellular components could help to 
determine when PMN will originate metastatic disease, improving early diagnosis.  
2. Extracellular Vesicles (EVs) 
2.1 Extracellular Vesicles mediate intercellular communication 
Intercellular communication requires cell-to-cell contacts through highly-organized 
cell-cell structures such as gap junctions, intercellular bridges or synapses (short-
distance communication) and/or involves the secretion of specific factors for long-
distance communication. Cells derived secreted factors can be molecules directly 
secreted in the extracellular space (the so called secretome) or Extracellular Vesicles, 
a heterogeneous population of vesicles whose size varies between a range of 30 to 
1000 nm constituted by a lipid bilayer and containing all the known families of 
biomolecules {Mittelbrunn M. and Sánchez-Madrid F., 2013}. 
EVs-mediated communication is conserved through evolution, being reported not only 
in mammals but also in bacteria, archea, fungi, parasites {Deatherage B.L., et al., 
2012} and plants {Regente M., et al., 2012}. In humans, the first study on EVs in the 
plasma was published in 1946 {Chargaff E. and West R., 1946} but only in 1983, after 
the demonstration of the role of EVs in the transferrin receptor turnover during 
reticulocytes to erythrocytes maturation, the modern idea of EVs was established in 
the scientific community {Pan B.T. and Johnstone R.M, 1983}. 
The study of EVs has undergone a great expansion in the last years (Figure 2), and 
nowadays the presence of these vesicles has been demonstrated in almost all biologic 
fluids (plasma, urines, saliva, synovial and cerebrospinal fluid, breast milk) {Raposo 
G. and Stoorvogel W , 2013}.  
Of note, EVs are also secreted by tumor cells. In the last year, the physiological role of 
EVs in cancer has been intensively investigated; in particular, it was established that 
tumor exosomes can inhibit antitumor immune response and promote angiogenesis 
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and metastasis, leading to the conclusion that these vesicles have pro-tumoral effect. 
At the same time, other studies demonstrated that tumor exosomes can present tumor 
antigens to dendritic cells, inducing antitumor immune response. For this reason, 
further studies on EVs in cancer are needed, taking into consideration that not all 
vesicles could exert the same function in all cancer types {Bobrie A. and Théry C., 
2013}.  
 
Figure 2: The number of studies on EVs is increased in the last years.  
The graph represents the number of papers per year that have Extracellular Vesicles as topic (source: PubMed; last 
update: December 2017) 
The growing interest on EVs is also proved by the foundation of the International 
Society for Extracellular Vesicles (ISEV) in 2011, to facilitate the communication and 
the exchange of information between groups who deal with this issue. On the same 
line, international databases such as  EVpedia {Kim D.K., et al., 2015}, ExoCarta 
{Mathivanan S., et al., 2012} and Vesiclepedia {Karla H., et al., 2012} were 
implemented to collect information about EVs proteomic, lipidomic and transcriptomic 
content. 
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2.2 Classification, enrichment and characterization of Extracellular Vesicles are 
matter of debate 
EVs can be divided in three main populations: apoptotic bodies, released by dying 
cells during apoptosis, exosomes and microvesicles, actively secreted by viable cells 
{Raposo G. and Stoorvogel W,  2013}. 
Excluding apoptotic bodies, whose characteristics are known, there is still a big 
confusion on the other EVs nomenclature. Indeed, these vesicles were not only 
identified with more than 20 different names according to their biogenesis, function, 
donor cells or biological properties but, according to different authors, the term 
“exosomes” was used to describe both vesicles coming from Multivesicular Bodies 
(MVBs), vesicles isolated after ultracentrifugation between 70000 and 100000g and 
all the extracellular vesicles with a biological function. Also the term “microvesicles” 
was used to identify both budding vesicles from plasma membrane, vesicles enriched 
after 10000g centrifugation and all the EVs {Gould S.J. and Raposo G., 2013}. Since 
there is still no universally accepted nomenclature, the ISEV suggests the use of the 
term “Extracellular Vesicles” to define all the secreted vesicles, regardless of their 
biogenesis, characteristics and donor cells phenotype {Simpson R.J., 2012}. 
Moreover, due to limitations in enrichment and characterization assays, EVs samples 
often contain heterogeneous population of vesicles, that are different in composition, 
properties and functions, depending on the assay used to enrich them from biological 
samples {Taylor D.D. and Shah S., 2015}. Nowadays, differential centrifugation is the 
method of choice to collect EVs, and it is indeed used in the majority of the studies 
often in combination with centrifugation on a density gradient, in order to 
differentiate between the desired vesicles subpopulation (that is expected to have a 
specific density) and other soluble secreted factors. Other approaches, including 
filtration, precipitation, size-exclusion chromatography and affinity binding on 
magnetic beads are used as well {Gardiner C., et al., 2016}. To overcome the problem 
of heterogeneity in isolation methodologies and to increase the transparency of 
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reporting data in EVs studies, in 2017 the EV-TRACK consortium created an open-
source knowledgebase in which a EV-METRIC measures for each specific work how 
much the reporting of generic and method-specific information is complete and allows 
the possibility to interpret and reproduce the experiments {Van Deun J., et al., 2017}. 
The heterogeneity in EVs studies is also complicated by the fact that, to date, the 
assays used to characterize the vesicles in a biological sample are western blot 
analysis, single particle tracking analysis, atomic force microscopy and electron 
microscopy, that are not only different in sensitivity, but are also able to better 
highlight different EVs characteristics. Furthermore, there are no specific markers 
that let scientists to univocally differentiate between microvesicles and exosomes. For 
this reason, the ISEV published some guidelines to standardize the definition of EVs 
{Lötvall J., et al., 2014}, as reported in Table 2. 
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Category 1 2 3 4 
Class  
Transmembrane or 
lipid-bound 
extracellular 
proteins 
Cytosolic proteins 
with membrane- or 
receptor-binding 
capacity 
Intracellular 
proteins not 
associated with 
plasma membrane 
or endosomes 
Extracellular 
proteins binding to 
membranes 
Examples 
Tetraspanins Endosomal proteins 
Mitochondrial 
proteins 
Acetylcholinesterase 
Phosphatidylserine 
binding proteins 
Membrane binding 
proteins 
Proteins of 
endoplasmic 
reticulum 
Extracellular 
Matrix proteins 
Integrins and cell 
adhesion molecules  
Signal transduction 
or scaffolding 
proteins 
Proteins of Golgi 
Apparatus 
Soluble secreted 
proteins 
    
Growth factor 
receptors 
 Nuclear proteins Serum albumin 
G proteins    
Table 2: Expected presence of proteins in EVs samples.  
As indicated by ISEV, at least one protein of each category 1 and 2 should be quantified in the EV preparations, proteins 
of category 3 should be absent in EVs sample and EVs association of proteins of category 4 should be demonstrated by 
other means (Adapted from Lötvall J., et al., 2014) 
2.3 Biogenesis of Extracellular Vesicles  
Despite all of the above-mentioned problems to standardize EVs enrichment and 
characterization, in the majority of the studies, the term “exosomes” is referred to 
small-size vesicles (30-100 nm) originating in the endosomal compartment, while the 
term “microvesicles” indicates all the vesicles that originate by the budding from the 
plasma membrane and whose size is comprised between 100 and 1000 nm (Figure 3).  
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Figure 3:  Schematic representation of Microvesicles and Exosomes origin.  
Exosomes have a size between 30 and 100 nm and originate from the endosomal compartment, while microvesicles are 
bigger (100 to 1000 nm) and originate by budding from the plasma membrane (Adapted by Raposo G. and Stoorvogel 
W., 2013) 
Table 3 summarizes the characteristics usually associated to the two vesicles 
populations according to their origin {Mathivanan S., et al., 2010}.  
 Exosomes Microvesicles 
Size (diameter) 30–100 nm 100–1000 nm 
Flotation 
density  
1.10–1.21 g/mL NA 
Morphology Cup-shaped Various shape 
Lipid 
composition 
LBPA, low phosphatidylserine exposure, 
cholesterol, ceramide, contains lipid rafts, 
sphingomyelin 
High phosphatidylserine 
exposure, cholesterol 
Protein 
markers 
Alix, TSG101, CD63, CD81, CD9 
Selectins, integrins, CD40, 
metalloproteinases 
Site of origin Multivesicular Bodies Plasma membrane 
Release Constitutive and regulated Regulated 
Mechanism of 
discharge 
Exocytosis of MVBs 
Budding from plasma 
membrane 
Cargo 
Proteins, miRNA, mRNA, lipids, 
mitochondria 
Proteins, miRNA, mRNA, 
lipids 
Table 3: Principal characteristics that distinguish exosomes from microvesicles.   
Abbreviations: HSP70, heat shock protein family A member 8; LBPA, lyosbisphosphatidic acid; MV, microvesicles; MVBs, 
multivesicular bodies; NA, not assessed; TSG101, tumor susceptibility gene 101. (Adapted from Mathivanan S., et al., 
2010) 
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2.3.1 Exosomes originate from Multivesicular Bodies 
After the formation of the Intraluminal Vesicles (ILVs), early Endosomes mature into 
MVBs through the activation of the 4 multiprotein complex called the Endosomal 
Sorting Complex Responsible for Transport (ESCRT)-0, -I, -II, -III. In particular, ILVs 
formation seems to be promoted by the presence of tetraspanins- and 
Phosphatidylinositol 3-Phosphate- rich domains. These molecules are able to 
sequentially recruit the proteins of the ESCRT complex to bind ubiquitinated proteins 
and to induce the inward budding of endosomal membrane that forms the vesicles, 
involving also ancillary proteins such as ALIX {Kalra H., et al., 2016}. For this reason, 
the commonly used markers for exosomes are TSG101 (a member of the ESCRT-I 
complex), CD63, CD81, CD9 (members of the tetraspanins family), and ALIX. Finally, 
mature MVBs can either fuse with lysosomes to promote the degradation of their 
cargo, or with the plasma membrane to release ILVs and their content in the 
extracellular space. This process is mediated by cytoskeleton –associated or –non 
associated proteins (kinesines, myosins, small GTPases and SNAREs proteins) that 
deliver the MVBs to the plasma membrane and promote their fusion {Cocucci E. and 
Meldolesi  J., 2015}. Among small GTPases, almost 70 proteins of the RAB and RAB-
like family were identified in humans to control budding, motility, docking and fusion 
of vesicles to acceptor membranes {Zerial M. and McBride H., 2001}. By a short-
hairpin RNAs-based screening, Ostrowski and colleagues demonstrated that the Ras-
Related proteins RAB27A and RAB27B have a non-redundant role in the exosomes 
secretion pathway, as they promote the vesicles docking to the plasma membrane in 
HeLa cells {Ostrowski M., et al., 2010}. Moreover, it was demonstrated that the 
knock-down of RAB27A in mouse mammary carcinoma cells prevent metastasis 
formation {Bobrie A., et al., 2012} and that human melanoma cells that have high 
metastatic capability correlate with high levels of RAB27A mRNA {Peinado H., et al., 
2012}, suggesting a pro-tumoral and pro-metastatic function of this protein in cancer 
progression. 
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2.3.2 Microvesicles originate from the plasma membrane 
Microvesicles release is usually a very rapid and calcium-depending mechanism. The 
increase of intracellular calcium induces the activation of calcium-depending 
enzymes, such as translocases, that mediate the formation of cholesterol-, 
sphingomyelin-, phosphatidylserine- and ceramide- rich domains on the plasma 
membrane. As a consequence, proteins with phospholipidic anchors, cytoskeletal 
proteins and heat-shock proteins accumulate in those lipid rafts. Due to the particular 
lipids and proteins composition, the plasma membrane bends outward in a process 
promoted by enzymes such as calpains that induce cytoskeleton disassembly in that 
specific region. Vesicles budding is mediated by a signaling cascade that starts from 
ADP-ribosylation factor 6 and ends with the phosphorylation of the myosin light chain 
to induce actomyosin contraction {Cocucci E. and Meldolesi  J., 2015}.  
2.4 Extracellular Vesicles contain biological molecules 
It is now well established that EVs can deliver all the known biological molecules 
(proteins, lipids, metabolites and nucleic acids), but it is very difficult to define 
components that are univocally conveyed by exosomes or microvesicles because EVs 
content is distinctive of the donor cell and of its functional and metabolic conditions at 
the moment of the release {Tetta C., et al., 2013}. 
2.4.1 Extracellular Vesicles influence gene expression in target cells through mRNA 
delivery 
The horizontal transfer of genetic material through EVs was discovered in 2007 
{Valadi H., et al., 2007}. Of note, in 2008 Skog and colleagues demonstrated that 
mRNAs are not only delivered by EVs but are also translated by target cells, since 
they measured a positive luciferase signal in endothelial cells after the uptake of EVs 
released by glioblastoma donor cells transfected with the luciferase gene {Skog., et al., 
2008}. In this study, it was also demonstrated that the EVs transcriptome is not an 
exact mirror of the donor cells transcriptome, but is enriched in specific RNAs, 
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indicating a high level of cargo selection during EVs biogenesis and suggesting the 
possibility to use those RNAs as biomarkers. Indeed, vesicles enriched from primary 
glioblastoma cells contain almost 2000 RNAs involved in migration, proliferation, 
histone modification and immune response modulation pathways that are 380 times 
more enriched respect to the donor cells. On the other hand, 1200 RNAs were found 
90 times less enriched. In particular, ribosomal RNAs are always down-represented in 
EVs, so the absence 18S e 28S in EVs sample is widely used as quality control {Lässer 
C., et al., 2012}. Moreover, since it was reported that RNAse-treated EVs lose their 
ability to induce a phenotype in target cells, {Deregibus M.C., et al., 2007}, it was 
hypothesized that donor cells convey nucleic acids to EVs and transfer them in a way 
that prevents their degradation {Colombo M., et al., 2014}. 
2.4.2 Non-coding RNAs in Extracellular Vesicles can be used as biomarkers 
The increasing interest in the study of EVs-delivered micro RNAs (miRNAs) is also 
due to the fact that these molecules can be used as biomarkers for tumors: indeed, 
EVs miRNAs profiling in biological fluids could become a non-invasive analysis for 
cancer diagnosis, as was reported for the staging of ovarian cancer {Taylor D.D. and 
Gercel-Taylor C., 2008} and for the possibility to early detect a relapse after acute 
myeloid leukemia {Hornick N.I., et al., 2015}. The use of EVs miRNAs as biomarkers 
can be extended also to other diseases, as it was demonstrated that neuronal cells 
infected by prions release EVs that contain a characteristic miRNAs profile, allowing 
an early diagnosis for a disease that, so far, can be diagnosed post-mortem 
{Bellingham S.A. et al., 2012}. 
Moreover, not only miRNAs but also others non-coding RNAs (tRNAs, SRP-RNAs, Y-
RNAs and vault-RNAs) are selectively conveyed to vesicles and are able to induce a 
long-term alteration in target cells of their genetic expression {Huang X., et al., 2013}. 
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2.4.3 Lipids on Extracellular Vesicles membrane have both structural and biological 
functions 
Lipids are essential components of EVs, as they represent almost 2/3 of exosomes’ 
volume {Kreimer S., et al., 2015}. EVs membrane is composed by phospholipids 
(sphingomyelin and phosphatidylserine above all), ceramide, cholesterol and 
ganglioside GM3 {Choi D.S., et al., 2013}. The distribution of these molecules mainly 
depends on the vesicles origin: indeed, the lipidic composition of vesicles released from 
the plasma membrane is very similar to the one of the donor cells’ membrane, while 
exosomes usually have higher cholesterol levels {Osteikoetxea X., et al., 2015}. 
In addition to structural functions, the lipids carried by EVs can exploit biological 
functions on target cells, for example as it was demonstrated for cancer-derived EVs, 
in which sphingomyelin on the vesicles membrane has a pro-angiogenic function, 
promoting endothelial cells migration to form new vessels {Kim C.W, et al., 2002}. On 
the other side, lipid rafts enriched in cholesterol, sphingomyelin and ceramide and 
present in EVs can induce apoptosis in cancer cells by activating the NOTCH 
pathway {Beloribi S., et al., 2012}. 
2.4.4 Proteins in Extracellular Vesicles are characteristics of vesicles subtypes and 
donor cells 
EVs proteome has been studied both by semi-quantitative methods such as western 
blot and immune electron microscopy and by high-throughput methods such as mass 
spectrometry, liquid chromatography and flow cytometry. 
Searching in ExoCarta and Vesiclepedia databases it is possible to understand that 
basically all the known families of proteins have been detected in EVs isolated both 
from cell culture media and biological fluids. In particular, as discussed above, these 
vesicles seem to be enriched in proteins involved in MVBs formation (ALIX, TSG101) 
and docking (Annexins, Flotillin-1, RAB GTPases), in tetraspanins (CD9, CD63, 
CD81) and in Heat Shock Proteins (HSP60, HSP70, HSP90), that are often considered 
as exosomes markers. There are also evidences of a conserved presence of metabolic 
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enzymes, ribosomal proteins, ubiquitinated proteins, ATPases, adhesion molecules 
and proteins of the cytoskeleton {Mathivanan S., et al., 2010}, as well as 
metalloproteinases, glycoproteins and integrins {Kalra H., et al., 2016}.  
Several studies tried to identify specific markers to distinguish exosomes from 
microvesicles, but, up to now, there are not conclusive data. Kowal and co-workers 
analyzed EVs released by dendritic cells after their fractionation by differential 
centrifugation at 2000, 10000 and 100000g, demonstrating that tetraspanins, TSG101 
and Syntenin-1 are effectively enriched in the population resulting after 100000g 
ultracentrifugation, while Flotillin-1, Actin, HSP70 and Major Histocompatibility 
Complex (MHC) -I and –II were identically represented in all of the vesicles 
populations {Kowal J., et al., 2016}. Finally, it is important to consider the presence of 
specific proteins in donor cells: for example, neutrophils-derived EVs contain 
proteolytic enzymes {Gasser O., et al., 2003}, epatocytes-derived EVs contain enzymes 
involved in detoxification processes {Conde-Vancells J., et al., 2008} and cancer cells-
derived EVs contain proteases and growth factors involved in tumor progression 
{Minciacchi V.R., et al., 2015}. 
2.5 Tumor derived Extracellular Vesicles are key players in Pre-Metastatic Niche 
formation 
It has been shown that tumor cells release a larger amount of EVs in comparison with 
normal cells {Al-Nedawi K., et al., 2009} and that some stimuli, such as hypoxia that 
normally occurs in a fast-growing tumor mass, promote the production of EVs and 
modify their composition {Park J.E., et al., 2010}. Taken together, these evidences 
lead to the conclusion that EVs secretion, composition and function are altered during 
tumor progression and that EVs play an important role in tumor-host crosstalk, 
facilitating tumor growth and spreading (that is, PMN formation) {Zhang H.G., et al., 
2014}. 
Tumor cells-derived EVs have been shown to contribute to PMN formation by 
transferring their cargo (genetic material, metabolites and proteins) to stromal cells 
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which populate PMNs {Ratajczak J., et al., 2006}, that are thus reprogrammed 
towards a pro-metastatic and a pro-inflammatory phenotype in a cancer type and  
pre-metastatic organ depending manner. For example, Peinado and co-workers 
demonstrated that B16-F10 murine melanoma cells -derived exosomes are able to 
horizontally transfer the hepatocyte growth factor receptor Met to bone marrow 
progenitors cells, that would acquire pro-angiogenic and pro-migratory properties. 
This resulted in BMDCs exit from the bone marrow to contribute to the formation of 
PMNs in lungs. The same vesicles also promoted vascular leakiness in lung PMNs, 
inducing a pro-inflammatory response by increasing the expression of cytokines and 
chemokines which, in turn, recruit BMDCs to the lung {Peinado H., et al., 2012}.  
Moreover, it was demonstrated that integrins expressed on breast and pancreatic 
cancer cells-secreted exosomes determine metastasis organotropism: indeed, the 
integrin α6β4 heterodimer on the surface of tumor- derived exosomes promotes their 
homing to lung PMNs, whereas αvβ5 targets them to liver PMNs {Hoshino A., et al., 
2015}. Furthermore, Sung and colleagues hypothesized a role of EVs in regulating 
directional cell movement through tissues, in a process that is dependent on integrins/ 
FN interaction. Indeed, they showed that fibrosarcoma cells secrete FN-coated 
exosomes at the leading edge that bind collagen fibrils and then interact with cellular 
integrin receptors, facilitating integrin clustering and strong adhesion formation and 
leading to accelerated migration (Figure 4) {Sung B.H., et al., 2015}. 
 
Figure 4: FN-coated EVs determine directional cells movement through tissues. 
The unstable protrusions make the cells unable to migrate effectively (a). The secretion of FN-coated exosomes allows 
cells to reinforce nascent adhesions and stabilize protrusions (b). FN-coated exosomes promote effective and 
directional motility (c). (Adapted from Sung B.H., et al., 2015) 
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Finally, not only the convey of proteins in EVs is highly regulated and can determine 
organotropic metastasis, but also the genomic content (in particular miRNAs) is 
packaged selectively within EVs and is involved in PMN formation, as it was reported 
for brain metastasis, in which tumor-derived microvesicles suppress glucose uptake 
by stromal cells through the transfer of miR-122 and the  inhibition of pyruvate 
kinase, increasing glucose availability in PMNs to attract tumor cells {Fong M.Y., et 
al., 2015}. 
2.6 Extracellular Vesicles in clinics: promising biomarkers and therapeutic targets to 
block PMN establishment  
Given their role in PMN formation, their persistence and considered their stability, 
abundance and easy accessibility in body fluids, EVs are the most promising 
biomarkers for assessing the risk of tumor progression and metastasis. Indeed, a 
retrospective study on a cohort of patients with stage III melanoma demonstrated 
that exosomal levels of the melanoma-specific protein Tyrosinase-Related Protein 2 
correlate with metastatic progression {Peinado H., et al., 2012}, while the detection of 
exosomal miR-105 in the serum of breast cancer patients has been shown to occur at 
an early stage {Zhou W., et al., 2014}. These evidences lead to the hypothesis that 
addressing composition of EVs in body fluids of cancer patients can predict both 
metastatic potential and organotropism before their clinical detection. On the other 
hand, these vesicles could be therapeutic targets to block PMN formation and 
metastatic colonization.  
Furthermore, since exosomes are able to induce a reprogramming of systemic energy 
metabolism thus facilitating disease progression, a similar exosome-based strategy 
could be applied to hinder PMN formation: for example, engineered exosomes might 
facilitate the delivery  of molecules that inhibit the repression of glucose uptake by 
stromal cells in brain PMNs {Peinado H., et al., 2017}.  
Regarding the use of EVs for diagnostic purpose, proof-of-principle studies have 
demonstrated that exosomes loaded with superparamagnetic iron oxide nanoparticles 
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or iodine isotopes enables sensitive magnetic resonance or radiographic tracking, 
demonstrating that approaches of non-invasive imaging of PMN formation in vivo are 
possible {Zhu L., et al., 2014}. 
Technical limitations in PMNs analysis (i.e. the requirement for in vivo microscopy) 
have hindered the analysis of EV dynamics within PMNs; for this reason, it is 
important to better define the EVs cargo in order to identify tumor-specific 
biomarkers that can be then validated in patients {Gold B., et al., 2015}.  
Finally, a full characterization of secreted vesicles sub-populations and of their 
associated cargo is necessary to understand how EVs affect PMN formation, defining, 
for example, how EVs form, adhere, fuse and educate recipient cells within PMNs, 
how long does EV-mediated education of recipient cells lasts, and if EVs-mediated 
education could be reverted to impair metastasis formation and spreading. 
3. Melanoma 
3.1 Cutaneous melanoma is among the most aggressive and treatment-resistant 
human cancers 
Melanoma represents the 4% of all dermatologic cancers but it is responsible for 
approximately 80% of skin cancer mortalities and its survival rate dramatically 
decreases once the tumor has metastasized: indeed, only 14% of patients with 
metastatic melanoma survive for five years after the diagnosis {Miller A.J. and 
Mihm M.C. Jr, 2006}.  
This cancer originates from melanocytes, that are neural-crest derived cells located 
not only in the stratum basale of the epidermis and in hair follicles, but also in the 
ear’s cochlea and the eye’s uvea, as well as in the brain {Yamaguchi Y. and Hearing 
V.J., 2014}. These cells produce the pigment melanin, which is stored in specific 
organelles termed melanosomes, that are present within the cells in different 
maturation steps. In particular, immature melanosomes (stages I and II) lack 
pigment and are located in the central cytoplasm, while mature melanosomes 
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(stages III and IV) are heavily pigmented and are placed at distal dendrites o f the 
cells, being ready to be secreted {Raposo G. and Marks M.S., 2007}. Melanosomes 
secretion occurs in physiological conditions to transfer the melanin from melanocytes 
to keratinocytes in response of ultraviolet radiation. It was also hypothesized that 
drug resistance in melanoma is partially due to melanosomes trafficking, that export 
the chemotherapeutic agents out of the tumor cells {Chen K.G., et al., 2006}, but a 
direct role of those organelles in promoting melanoma tumorigenesis has yet to be 
defined. 
Melanoma growth is a stepwise process in which melanocytes proliferate from the 
basal epidermis toward the upper epidermis during the primary stages (melanoma in 
situ). Later, melanoma cells invade the dermis, engaging contacts with blood vessels 
to start metastatization. The Clark’s model describes the histological changes 
associated with the progression from melanocyte to malignant melanoma {Clark W.H. 
Jr, et al., 1984}. It was demonstrated that in each stage specific gene mutations affect 
molecular pathways, driving the process of nevi formation and the subsequent 
development of dysplasia, hyperplasia, invasion and metastasis {Miller A.J. and 
Mihm M.C. Jr, 2006}. In particular, mutations in the Neuroblastoma RAS Viral 
Oncogene Homolog (NRAS) and in the B-Raf Proto-Oncogene, Serine/Threonine 
Kinase (BRAF), that are upstream the Mitogen-Activated Protein Kinase (MAPK) 
pathway, induce higher melanocytes proliferation, with the formation of benign nevi. 
These lesions could remain in this stage or become pre-malignant lesions (dysplastic 
nevi) characterized by the loss of function mutations in CDKN2A (Cyclin-Dependent 
Kinase Inhibitor 2A) and PTEN (Phosphatase and Tensin homologue), that control 
the PI3Kinase/AKT pathway. The combination of NRAS and BRAF mutations with 
the loss of CDKN2A and PTEN drives the melanoma radial growth phase. Vertical 
growth phase is the following step, in which melanoma cells loose cell-cell adhesion 
and penetrate through the basement membrane as a consequence of the loss of E-
cadherin and gain of N-cadherin expression. Finally, the loss of E-cadherin leads to 
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the dissociation of β-catenin from the cell adhesion complex. Then, β-catenin 
translocates to the nucleus and positively regulates expression of CyclinD1 and of 
Microphthalmia-Associated Transcription Factor (MITF), which are associated to 
melanoma cell proliferation, survival and invasion {Prasad C.P., et al., 2015} (Figure 
5). 
 
Figure 5: Model of melanoma progression. 
The biological events and the molecular lesions that characterize melanoma progression are related to the tumor 
staging according to the Clark’s model. BRAF mutation and activation of the MAPK pathway lead to the limited growth 
of benign lesions within the epidermis (Benign Nevus). Then, mutations of CDKN2A and PTEN cause the formation of 
pre-malignant lesions that weak the basement membrane (Dysplastic Nevus). The decreased expression of melanoma 
markers regulated by MITF leads to a decrease in cells differentiation and to dermis invasion (Radial Growth Phase). 
Subsequently, the control of cell adhesion is strikingly de-regulated and the tumor mass grow inside the dermis (Vertical 
Growth Phase). Finally, the loss of E-cadherin and the increased expression of N-cadherin, αVβ3 integrin, and matrix  
metalloproteinase 2 (MMP-2), as well as the loss of the melanocyte-specific gene melastatin 1 (TRPM1) cause the 
dissociation of melanoma cells from primary tumor and the growth at metastatic sites (Metastatic Melanoma). 
(Adapted from Miller A.J. and Mihm M.C. Jr, 2006 ) 
It was shown that mutations in BRAF gene at codon 600 (BRAFV600) occur at early 
stage in 50% of all melanomas. The most common BRAF mutations 
are BRAFV600E (almost 74% of BRAF mutations) and BRAFV600K (almost 20% of BRAF 
mutations), that result in the constitutive up-regulation of the MAPK pathway, 
thereby promoting cell proliferation and metastasis {Prasad C.P., et al., 2015}. Several 
studies have been performed to inhibit V600 mutated BRAF, leading to the approval 
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of Vemurafenib and Dabrafenib to target BRAFV600E and BRAFV600K, that, alone or in 
combination with other MAPK inhibitors, are able to induce rapid regression of 
metastatic melanoma. Unfortunately, after the immediate antitumor effect, in 
patients treated with BRAF inhibitors resistance often occurs {Monsma D.J., et al., 
2015}. The combination of BRAF targeted therapy with immunotherapy has even less 
positive effects {Luke et al., 2017}. For these reasons, recent studies have highlighted 
a mechanism that might be responsible for resistance to BRAF inhibitors, in order to 
find new approaches for future combinatorial therapy for malignant melanoma. For 
instance, it was shown that the signaling of Wingless-related integration site, Family 
member 5A (WNT5A) is involved in melanoma resistance to BRAF inhibitors in 
addition to MAPK and PI3K/AKT signaling. Indeed, it was demonstrated that 
different melanoma cell lines have variable WNT5A protein levels, that are very high 
in BRAF inhibitors-resistant cells, and this phenotype was confirmed in clinical 
specimens, since patients who relapsed after BRAF inhibitors therapy showed 
increased positivity for WNT5A expression {Anastas J.N., et al., 2014}. WNT5A 
signaling in melanoma cells can trigger the PI3K-AKT pathway, whose up-regulation 
occur during melanoma progression, as well as it can activate EGFR signaling by 
MITF inhibition {Prasad C.P., et al., 2015}. Moreover, targeting WNT5A is a 
promising therapeutic option for melanoma because WNT5A promotes migration and 
invasion in both normal and BRAF inhibitors-resistant melanoma cells {Weeraratna 
A.T., et al., 2002}. 
BRAF inhibitors-resistant melanoma cells can also educate neighboring cells to 
acquire resistance trough the secretion of EVs: indeed, it was recently published that 
BRAFV600E inhibitor–sensitive metastatic melanoma cells become resistant after the 
uptake of EVs secreted by neighboring drug-resistant melanoma cells carrying 
PDGFRβ, that is a resistance-driver {Vella L.J., et al., 2017}. Furthermore, the 
miRNA cargo in the EVs of BRAFV600E malignant melanoma cells is altered after the 
treatment with BRAF inhibitors, suggesting that molecules present in EVs may 
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promote disease progression in patients that receive BRAF-targeted treatment 
{Lunavat T.R., et al., 2017}. Since the majority of BRAF inhibitors target only 
BRAFV600E mutations, it will be important to perform further studies on melanoma 
cells bearing different BRAF mutations to better understand which molecules carried 
by EVs drive the acquisition of resistance after BRAF inhibitors treatment. 
3.2 Extracellular Vesicles in melanoma 
Several studies reported the secretion of EVs in melanoma, even if it is difficult to 
clearly identify which EVs subpopulations are secreted by melanoma cells and if one 
is predominant above the others to sustain cancer progression (see section 2.1). 
Indeed, it was reported that malignant melanocytes maintain their capability to 
produce melanin and to transfer it to adjacent keratinocytes trough melanosomes 
secretion {García-Silva S. and Peinado H., 2016}. At the same time, it is well 
established that metastatic melanomas secrete high amounts of exosomes, even if 
NanoSight analysis demonstrated that the size distribution and number of those 
organelles in the plasma of melanoma patients did not differ based on melanoma 
clinical stage. Exosome protein concentrations in subjects with Stage IV disease 
affected the survival rate. Indeed, the prognosis for patients with protein-rich 
exosomes (>50 µg/mL-1) has been demonstrated to be worse than the one for patients 
with protein-poor  exosomes (<50 µg/mL-1) {Peinado H., et al., 2012}. The predominant 
role played by those organelles in metastatic melanoma was also demonstrated by 
their capability to promote mobilization of bone marrow progenitors to PMN in distal 
sites, by increasing vascular permeability in metastatic tissues and by contributing to 
the organotropism of metastatic cells {Hoshino A., et al., 2015}. Despite these findings, 
those studies did not evaluate the relevance of melanosomes, since it is not clear if 
ultracentrifugation and the subsequent fractionation of EVs pellet on sucrose cushion 
is enough to separate melanosomes from exosomes {García-Silva S. and Peinado H., 
2016}. 
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Moreover, the role of EVs in primary melanoma is still not clearly understood 
{García-Silva S. and Peinado H., 2016}. Dror and colleagues showed that primary 
melanoma cells secrete mainly melanosomes, that could be separated from 
exosomes by centrifugation of the cell culture medium at 20000g {D’Souza -Schorey 
C. and Clancy J.W., 2012 }. Pigmented melanosomes are transferred to dermal 
fibroblasts surrounding melanoma in situ and promote a cancer-associated 
phenotype up-regulating genes associated with proliferation, motility and 
inflammation. In this experiment, the authors postulated that primary melanoma 
cells hijack melanosome secretory pathways to establish a protective niche, 
allowing tumor cells to grow and to invade the dermis {Dror S. et al., 2016}. 
Considering what mentioned above about the role of exosomes in promoting 
metastatic progression {Peinado H., et al., 2012} and the role of melanosomes in the 
early stages of melanoma tumorigenesis {Dror S. et al., 2016}, it is tempting to 
hypothesize that the secretion of different EVs subpopulations could be an adaptive 
mechanism employed by melanoma cells to corrupt the surrounding 
microenvironment favoring tumor progression, and further studies are needed to 
demonstrate which are the characteristics of those vesicles in order to identify new 
therapeutic strategies. 
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AIM OF THE PROJECT 
Depending on the aggressive state of tumor cells, the extracellular environment is 
expected to have qualitative and quantitative differences in its composition. A 
comparative proteomic characterization of the exosomes secreted by isogenic 
melanoma cell lines to address different contribution to the pre-metastatic niche 
establishment in metastatic versus primary tumor cells has never been performed.  
In this study, we optimized a deep quantitative proteomics protocol to analyze 
exosomes and secretome composition, as well as the proteome, of primary tumor and 
metastasis-derived isogenic melanoma cell lines, and we set assays to investigate how 
the qualitative and quantitative differences we observed in primary tumor versus 
metastatic microenvironment can affect the behavior of cancer cells. 
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MATERIALS AND METHODS 
1. DNA procedures  
1.1 Agarose gel electrophoresis 
DNA samples were loaded on 1% agarose gels made in TAE buffer containing Gel Red 
(1:10000; Biotium, Fremont, CA, USA), and then samples were run at 90 V until 
desired separation was achieved. DNA bands were visualized under a UV lamp. 
1.2 Transformation of competent cells 
Plasmid DNA was added on a vial containing Stbl3 E.Coli competent cells (Invitrogen, 
Carlsbad, CA, USA) and incubated on ice for 30 minutes. After 30 seconds of  heat-
shock at 42°C to promote the entrance of DNA, Stbl3 cells were left on ice for 5 
minutes and allowed to grow in Luria-Bertani (LB) medium at 37°C for 60 minutes. 
Bacteria were harvested by gentle centrifugation (4000rpm for 5 minutes) and 
resuspended in 50µL of LB before plating them onto LB-Agar plates containing the 
appropriate antibiotic for the positive selection of bacterial colonies. Plates were 
incubated overnight at 37°C. 
1.3 Plasmid isolation from individual bacterial colonies 
Clones picked from individual colonies were allowed to grow at 37°C in 5 mL of LB 
containing the appropriate antibiotic and then harvested by centrifugation at 16000g 
for 5 minutes. The Wizard Plus SV Minipreps Kit (Promega, Fitchburg, WI, USA) was 
used to isolate intact plasmid DNA in TE buffer according to manufacturer’s 
instructions. 
1.4 Large scale plasmid preparation 
Stbl3 E.Coli competent cells containing plasmid DNA were grown overnight at 37°C 
into 500mL of LB containing the appropriate antibody. Plasmid DNA was isolated 
from these cells using the NucleoBond®Xtra Maxi Kit (Macherey-Nagel, Duren, 
Germany) according to manufacturer’s instructions. 
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2. Cell Culture 
2.1 Cell lines and culture conditions 
Isogenic melanoma cell lines isolated from the primary tumor and the metastasis of 
the same patient were used to study melanoma metastasis progression. Providing 
that, coming from the same patient, these cells share the same karyotype, this model 
allowed us to be focused on differences in the proteomic content of cells and their 
secreted vesicles.  
In particular, we used WM115 and IGR39 as primary tumor cells, both established 
from a primary (achromic) cutaneous malignant melanoma, and WM266.4 and IGR37 
as metastatic melanoma cells, established from skin and lymph node metastatic sites 
respectively. All of these cells were available in our cell culture facility and are 
described as tumorigenic in mice. Moreover, WM115 and WM266.4 cell lines were 
isolated from a female patient and have V600D mutated BRAF, while IGR39 and 
IGR37 cells were established from a male patient and have the V600E BRAF 
mutation, most common in melanoma (source: Cancel Cell Line Encyclopedia). 
Isogenic cell lines were cultured in DMEM medium (Lonza, Basel, Switzerland) 
supplemented with 10% Fetal Bovine Serum (FBS), 1% penicillin-streptomycin 
(Microtech, Naples, Italy) and 4mM L-Glutammine (Life Technologies, Carlsbad, CA, 
USA) at 37°C in a 20%O2 and 5% CO2 humidified incubator. All cells were regularly 
tested for the absence of mycoplasma. 
2.2 MTT assay. 
Methyl-thiazol-tetrazolium (MTT) assay was performed as previously described {Riss 
T.L. et al., 2013}. For each cell line tested, 104 cells per well were plated in a 96-wells 
plate and cultured in ultracentrifuged medium for 48 hours or in serum-free medium 
for 20 hours. MTT (0.5 mg/mL) was added to each plate and incubated for 4 hours to 
allow formazan crystals formation. After medium removal, DMSO was added to each 
well and plates were leaved in agitation for 5 minutes at room temperature to allow 
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formazan crystals resuspension. For each well, the absorbance at 570 nm was read at 
the Victor multilabel plate reader machine (Perkin Elmer, Waltham, MA, USA). For 
each cell line, three biological replicates were done and measured in triplicates. 
2.3 Growth curve 
Primary tumor and metastatic melanoma cells were plated at 105 cells/mL in a six 
well plate. Growth curve was built by counting cells everyday by using a Coulter 
Counter instrument (Beckman Coulter, Brea, CA, USA). The experiment was 
conducted as biological replicates and technical triplicates. Statistical analysis and 
graphic presentations were done using GraphPad Prism Software version 4.01 
(GraphPad Software, La Jolla, CA). 
2.4 RAB27A Knock Down of  metastatic melanoma cells 
Mission® Oligos shRNAs 5’-CCAGTGTACTTTACCAATATA-3’ (Oligo1) and  
5’-CGGATCAGTTAAGTGAAGAAA-3’ (Oligo2) were purchased from Sigma-Aldrich. 
These sequences were chosen in exone-junction region of the RAB27A gene to improve 
Knock Down (KD) efficiency and cloned in a lentiviral shRNA expression system 
pLKO3.1 (gift of Prof. Giovanni Tonon from Università San Raffaele, Milan, Italy) to 
stably KD RAB27A in WM266.4 and IGR37 cell lines. 
2.4.1 ShRNA cloning into pLKO3.1 plasmid 
ShRNA oligos were annealed at room temperature and cloned into pLKO.1 puro 
plasmid upon digestion of the vector with AgeI and EcoRI restriction enzymes (New 
England Biolabs, Ipswich, MA, USA), followed by ligation reaction using Quickligase 
(New England Biolabs). Stbl3 E.Coli cells were transformed  and positively selected 
clones were screened for cloning efficiency by sequencing of the pLKO-1 puro plasmid. 
2.4.2 Lentivirus production in HEK293T cells 
HEK293T cells were plated on 10 cm dishes in order to obtain for the day after cells at 
70% of confluence. Cells were transfected with 1mL of a Oligo mix composed by 500μL 
of the mix containing 10μg of pLKO3.1 plasmid carrying Oligo1, Oligo2 or a Scramble 
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(Scr) sequence, the third generation lentiviral packaging vectors (pMD2.g_Env, 
pMDL-RRE_Gag&Pol, pRSV_Rev), 2M CaCl2 and 0.1% Tris-EDTA pH8 (TE), added 
dropwise to 500μL of HBS solution (50 mM HEPES, 280 mM NaCl, 1.5 mM 
Na2HPO4, pH to 7.0). The reaction was left for 5 minutes at RT to allow the 
formation of complexes and then was added to 9 mL of complete cells medium and left 
over-night at 37°C. The day after, viral particles were concentrated by replacing 
HEK293T cells supernatant with 5 mL of fresh medium. 
2.4.3 WM266.4 and IGR37 cells lentiviral infection 
5 mL of HEK293T medium containing concentrated viral particles were filtered with 
a 0.45µm filter and used to infect 5x105 WM266.4 cells in a 6 wells plate or 5x105 
IGR37 cells in a 10cm dish. To increase infection efficiency, polybrene (8µg/mL) was 
added to the viral supernatant.  
RAB27A-KD cells were positively selected for puromycin resistance (final 
concentration: 1µg/mL) starting from 48h after the infection. 
2.5 Colony formation assay 
A colony formation assay was used to test the clonogenic ability of both primary 
tumor and metastatic melanoma cells as previously described {Franken N.A., et al., 
2006}. Briefly, 1.5x103 WM115 or WM266.4 cells and 2x103 IGR39 or IGR37 cells were 
carefully resuspended in 5mL of complete DMEM and seeded in 6 wells to allow the 
formation of the colonies. After 15 days, colonies were stained with Crystal Violet and 
counted using FIJI/ImageJ Software {Schindelin J., et al., 2012} in collaboration with 
Stefano Freddi at MolMed. 
2.5.1 Colony formation assay with conditioned media 
To investigate if RAB27A KD have an impact on a vesicles population that could 
influence the clonogenic ability of metastatic melanoma cells, EVs were isolated from 
a 15cm dish of RAB27A-wild-type (Scr) or -KD donor cells with the ultracentrifugation 
protocol and carefully resuspended in the same volume of EVs-depleted DMEM to 
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maintain the physiological EVs concentration. The supernatant of the 100000g 
ultracentrifugation contained the soluble factors released by the cells together with 
the EVs, so it was filtered with a 0.22µm filter and used in parallel with resuspended 
EVs sample to stimulate RAB27A-Scr or -KD cells. Stimulation of recipient cells was 
done for 6 hours in order to allow them to uptake EVs or soluble factors, then cells 
were seeded in 6 wells as previously described and colonies stained after 15 days 
(Figure 6). 
Figure 6: Schematic workflow of the colony formation assay with conditioned media  
The supernatant of either RAB27A-KD and -WT cells (Scramble) cells was ultracentrifuged to separate EVs from soluble 
secreted factors. The vesicle pellet was resuspended in the same volume of EVs depleted medium to maintain the 
physiological vesicles concentration and used in parallel with the secreted soluble factors containing sample to 
stimulate RAB27A-KD and –WT cells for 6 hours before plating. Colonies were stained after 15 days. 
The assay was repeated in at least 3 biological replicates in order to have a statistical 
significance of the results. Statistical analysis was performed with Prism GraphPad 
Software. 
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3. Extracellular Vesicles enrichment from conditioned media 
3.1 EVs harvesting by serial centrifugation  
DMEM medium were supplemented with 20% FBS and ultracentrifuged twice for 16h 
at 100000g to remove EVs coming from the serum, then diluted 1:2 with serum-free 
DMEM and supplemented with 1% penicillin-streptomycin and 4mM L-Glutammine, 
to generate EVs-depleted DMEM. 
Melanoma cells were plated at 50% of confluence. The day after, the medium was 
replaced with EVs-depleted DMEM and cells were grown for 48h to allow the release 
of EVs in the supernatant. The 48h time point was considered the best moment to 
collect EVs because cells were at 90% of confluency and over 95% of viability, that 
allowed us to have a good EVs concentration in the supernatant without possible 
contamination coming from apoptotic bodies. Cells viability was checked both by 
Erythrosine incorporation, MUSE®Count&Viability assay (MerkMillipore, Darmstadt, 
Germany) and MTT assay. 
Vesicles were enriched by serial centrifugation as previously described {Thery C. et 
al., 2006}. Conditioned media were clarified from cells and debris by centrifugation at 
low speed (5 minutes at 300g). Then, bigger vesicles were removed after 
centrifugation at 10000g for 30 minutes. The supernatant was filtered in a Stericup 
Vacuum Driven Sterile Filter (PVDF membrane, very low protein binding, pore size 
0.22 μm; MerkMillipore, Darmstadt, Germany), to eliminate protein aggregates and 
particles bigger than 0.22µm. The EVs pellet was obtained by ultracentrifugation of 
the filtered supernatant at 100000g for 90 minutes in a Beckman Coulter Optima L-
90K ultracentrifuge with a 50.2 Ti rotor (Beckman Coulter). Finally, EVs were 
washed twice with Phosphate Buffered Saline (PBS) by ultracentrifugation at 
100000g for 60 minutes (Figure 7). 
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Figure 7: Workflow of EVs enrichment from cells’conditioned media.  
The supernatant of donor cells (Conditioned medium) was centrifuged at low speed to discard cells and debris. Big 
vesicles were eliminated trough 10000g centrifugation and the supernatant was filtered to discard big particles and 
protein aggregates. The pellet obtained after the ultracentrifugation of the clarified supernatant at 100000g was 
washed in PBS. It contained a heterogeneous population of EVs, composed of both microvesicles and exosomes.  
(Adapted from Théry et al., 2006) 
The number of donor cells was 50x106 for Atomic Force Microscopy analysis and 
100x106 for Mass Spectrometry analysis, while for Western Blot analysis we used a 
number of donor cells that was sufficient to obtain 30 µg of protein lysate. 
For all the assays, EVs were not subjected to freeze/thaw cycles. According to the 
assay, the fresh EVs pellet was resuspended in an appropriate volume of PBS or EVs 
depleted medium or lysed in RIPA buffer (50mM TrisHCl pH8, 1% NP40, 0.5% 
Sodium Deoxycholate, 0.1% Sodium Dodecyl Sulfate, 150mM NaCl, 20mM Sodium 
Pyrophosphate, 2mM PhenylMethylSulfonyl Fluoride, 10mM Sodium Orthovanadate, 
50mM NaF) for Western Blot analysis or in Lysis Buffer (8M Urea, 100 mM Tris-HCl, 
10mM TCEP, 40mM CAM) for MS analysis. 
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3.2 EVs fractionation on iodixanol gradient.  
3.2.1 Discontinuos gradient fractionation 
To further investigate if EVs sample was not contaminated by other organelles, a 
fractionation of the ultracentrifuged EVs pellet on a discontinuous iodixanol gradient 
was performed as previously described {Sung B.H. et al., 2015}.  
EVs pellet was resuspended in 500µL of Buffer A, composed by 0.25M Sucrose (Carlo 
Erba Reagents, Milan, Italy), 10mM Tris-HCl, 1mM EDTA pH 7.4. Then, 40% (w/v), 
20% (w/v), 10% (w/v) and 5% (w/v) iodixanol solution were prepared by diluting 
OptiPrepTM (60% (w/v) iodixanol solution; Axis-Shield PoC, Dundee, UK) with Buffer 
A. The discontinuos gradient was created manually stratifying 20% (3mL), 10% (3mL) 
and 5% (2.5mL) iodixanol solutions in decreasing densities from the bottom to the top 
in a 14x89 polyallomer tube (Beckman Coulter) and adding EVs pellet in Buffer A on 
top of the gradient. 
Samples were ultracentrifuged at 100000g for 18h in a SW41Ti rotor (Beckman 
Coulter). A long ultracentrifugation time was chosen in order to eliminate protein 
aggregates that could have the same density of EVs, as usual for top-loaded gradients. 
Eleven fractions were collected from the top to the bottom of the tube. Each fraction 
was washed twice in 5mL of PBS by 100000g ultracentrifugation for 1 hour to remove 
iodixanol. 
3.2.2 Calculation of the density of each fraction 
The density of each fraction was measured plotting the absorbance read at the 
NanoVue (GE Healthcare, Little Chalfont, UK) on a calibration curve built on 40% 
(w/v) 20% (w/v) 10% (w/v) and 5% (w/v) iodixanol solutions. In particular, to build the 
calibration curve it was considered that the density of any gradient solution can be 
calculated using the equation ρ= (Vd+V1d1)/(V+V1), where ρ is the density of the 
solution, V and d are the volume and the density of the stock (60% iodixanol solution) 
respectively and V1 and d1 are the volume and the density of the diluent (Buffer A) 
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respectively. Knowing the amount of iodixanol and Buffer A in each solution and 
knowing that d=1.320g/mL and d1=1.030g/mL, the density (ρ) of each solution was 
calculated as reported in Table 4. 
% Iodixanol ρ g/mL 
5% 1.054 
10% 1.079 
20% 1.127 
40% 1.223 
Table 4: Calculated density of each iodixanol solution 
Calibration curve linearity and reproducibility was tested in order to be sure that 
experiments done in different days with fresh made or overnight stored at 4°C 
iodixanol solutions can be compared. 
To read the absorbance of the fractions and of iodixanol solutions, 20µL of each 
sample were diluted 1:10 twice (final dilution: 1:100), then 3 dilution of the same 
sample were read 3 times at the NanoVue and the average of the measurements was 
plotted on the calibration curve to calculate the density of each fraction. This protocol 
allows good gradient reproducibility in different samples (Figure 8). 
 
Figure 8: Reproducibility of the density gradient distribution of each fraction in different samples 
After the fractionation on discontinuos iodixanol gradient,the density of each fraction was calculated plotting the 
absorbance read at Nano Vue on the calibration curve built with the standard solution used to prepare the gradient. 
The graph summarizes the inferred densities calculated for 3 independent samples in 3 different days .  
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4. Protein Procedures 
4.1 Cells and EVs lysis 
For western blot analysis, cells were washed in PBS to remove serum proteins and 
then lysed on ice in RIPA buffer supplemented with Protease Inhibitor Cocktail 
(Sigma) directly in the cell culture plates using a cell-scraper. EVs lysis was 
performed in RIPA buffer on the ultracentrifuged pellet. 
For proteomics analysis, both cells and EVs pellet were lysed at room temperature in 
UA Buffer containing 8M Urea (MerkMillipore, Darmstadt, Germany) and 100mM 
Tris HCl. 
Cells membranes and nucleic acids were fragmented by 3 cycles of 30 seconds of 
sonication at 4°C using a Bioruptor® (Diagenode, Seraing, Belgium) and removed from 
the samples by centrifugation at 16000g for 20 min at 4ºC. 
Protein concentration of clarified supernatants was measured by the Bradford assay 
(Bio-Rad, Hercules, CA, USA) according to manufacturer’s instructions. 
4.2 Western Blot  
The desired amounts of proteins were loaded onto 1 mm thick CriterionTM gels for 
electrophoresis (Bio-Rad). Proteins were transferred to a nitrocellulose membrane 
(Bio-Rad) in a Trans-Blot®TurboTM  Transfer System (Bio-Rad). Ponceau staining was 
used to determine the efficiency protein transfer onto the filters. Filters were blocked 
for 1 hour (or overnight) in 5% milk in TBS supplemented with 0.1% Tween (TBS-T). 
After blocking, filters were incubated with the primary antibody, diluted in TBS-T 5% 
milk, for 1 hour at room temperature, followed by three washes of five minutes each 
in TBS-T. Filters were then incubated with the appropriate horseradish peroxidase-
conjugated secondary antibody diluted in TBS-T for 30 min. After the incubation with 
the secondary antibody, the filter was washed 3 times in TBS-T (5 minutes each) and 
the bound secondary antibody was revealed using the ECL method (Amersham) with 
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a ChemiDoc MP System (Bio-Rad). Densitometric analysis on RAB27a protein levels 
was performed with Image Lab 5.2 Software (Bio-Rad). 
4.3 Antibodies 
Antibodies used for western blot analysis were: mouse anti-human Fibronectin 
(ab26245 Abcam), rabbit anti-human RAB27A (HPA001333, Sigma), mouse anti-
human ALIX (2171, Cell Signaling), rabbit anti-human CD81 (HPA007234, Sigma), 
goat anti-human TSG101 (M-19, Santa Cruz), rat anti-human WNT5A (MAB645, 
R&D Systems), mouse anti-human Apolipoprotein E (Ab1906, Abcam) 
5. Immunofluorescence 
WT and RAB27A-KD WM266.4 cells were cultured for 24 hours in complete DMEM 
on gelatine-coated coverslips, then cells medium and soluble debris were removed 
with 3 washing in PBS. Cells were fixed with 4% paraformaldehyde for 10 minutes 
and permeabilised at room temperature with 0.25% TritonX-100 in PBS on ice. Cells 
were incubated with primary antibodies for 1 hour followed by secondary antibodies 
(Cy3, LifeTechnologies) for 30 minutes, at room temperature. Nuclei were stained by 5 
minutes incubation with DAPI (1:5000 in PBS). Coverslips were mounted in glycerol 
solution (20% glycerol, 50 mM Tris pH=8.4) to avoid mechanical deformation of the 
sample. Images were captured using a Leica inverted SP2 microscope with a laser 
scanning confocal system. 
6. Proteomics analysis 
6.1 Sample preparation 
To increase protein recovery, both cells and EVs lysis was performed in strong 
denaturing conditions in UA Buffer supplemented with 10mM Tris(2-
carboxyethyl)Phosphine (TCEP; ThermoFisher Scientific, Waltham, MA, USA) and 
40mM Chloroacetamide (CAM), to reduce and alkylate the sample simultaneously. 
This lysis condition was demonstrated to prevent the loss of sample that typically 
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occurs in the canonical in-solution digestion, in which centrifugation steps on FASP 
filters are needed to change the buffer between lysis, reduction and alkylation {Kulak 
N.A. et al., 2014}. 
6.2 Deep quantitative proteomics on isogenic melanoma cell lines and EVs 
We optimized a deep quantitative proteomics assay to analyze isogenic melanoma 
cells proteome and vesicles protein content, coupling the SILAC-based approach with 
Strong Cationic Exchange (SCX) peptide fractionation, in order to increase both 
proteome coverage and proteins quantitation accuracy, as represented in Figure 9. 
Cells were cultured in complete DMEM supplemented with 10% of dialyzed FBS and 
the required amounts of isotopically labeled Arginine (13C6 15N4, heavy and 13C6, 
medium) and Lysine (13C6 15N2, heavy and 4,4,5,5D4, medium) (CIL laboratories, 
Tewksbury, MA, USA). We chose heavy and medium labeling instead of the classical 
heavy and light labeling to avoid any possible contamination of serum proteins for 
EVs and secretome proteomics analysis, as they would be light labeled. For all SILAC 
analyses on EVs and soluble secreted factors, samples were mixed 1:1 normalizing on 
donor cells number. 
For deep quantitative analysis of cell proteome, 250µg of protein lysates 
(medium+heavy) were diluted from 8M Urea to 6M Urea with 100mM Tris HCl and 
digested 3 hours with Lys-C (WAKO Chemicals, Neuss, Germany). Then, samples 
were diluted to 2M Urea with 100mM Tris HCl and digested over night with Trypsin 
(Sigma-Aldrich, Saint Louis, MO, USA). For both the digestions, a 1:50 ratio 
(µgenzyme/µgprotein) was used.  
Digested peptides were acidified with 1% Trifluoroacetic Acid (TFA). Urea was 
removed from the sample by precipitation on ice for 10 minutes and centrifugation at 
3000g for 10 minutes. The supernatant was loaded on a Sep-Pak C18 Cartridge 
(Waters, Milford, MA, USA), that was previously equilibrated with 100% Acetonitrile 
(ACN) and washed 3 times with 1, 3 and 6 mL of 0.1% TFA. After washing the sample 
with 1, 5 and 6 mL of 0.1% TFA, peptides were eluted 2 times with 2 mL and once 
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with 1 mL in 0.1% TFA and 50% ACN, then the eluate was frozen and lyophilized 
over night. 
Lyophilized samples were resuspended in 1% TFA before fractionation on SCX resin 
beads (ThermoFisher Scientific, Waltham, MA, USA) equilibrated in 0.2% TFA. 
Peptides were eluted in 4 fractions with increasing concentration of Ammonium 
Acetate (75-125-200-300 mM Ammonium Acetate in 20% ACN, 0.5% Formic Acid, 
FA), while the 5th fraction was eluted in 20 mM Ammonium Hydroxide and 80% ACN. 
Solvents were removed from the sample with centrifugation in a SpeedVacTM Vacuum 
System and peptides were resuspended in 0.1% FA. 5µg of each eluted fraction was 
analyzed by combining UPLC with the Q-Exactive HF mass spectrometer 
(ThermoFisher Scientific, Waltham, MA, USA) on a 180 minutes gradient (Figure 9).  
Figure 9: Schematic workflow of the deep quantitative proteomics analysis of isogenic melanoma cell lines. 
Primary tumor and metastatic melanoma cells were cultured in DMEM supplemented with either heavy or medium -
labeled aminoacids, mixed 1:1 according to their number and lysed in strong denaturing, reducing and alkylating 
conditions. After digestion, peptides were fractionated in 5 samples through SCX and run on the Q-Exactive HF 
instrument in technical duplicates on a 180 minutes gradient to identify and quantify differentially expressed proteins.  
For deep quantitative proteomics on melanoma EVs, only tryptic digestion and 
desalting on C18 StageTip were performed as previously reported {Rappsilber J., et 
al., 2003}. All the peptides were eluted in one single fraction using a 80% ACN 0.1% 
FA solution and a 75 minutes gradient was used for MS analysis. 
For each assay, reverse-labeling experiments were performed to obtain statistical 
significance.  
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MaxQuant Software {Cox J. and Mann M., 2008} was used for protein identification 
and Perseus {Cox J. and Mann M., 2012} was used for quantification and statistical 
analysis. 
Statistically regulated proteins were clustered using EnrichR enrichment analysis 
{Kuleshov M.V., et al., 2016}. 
6.3 Secretome analysis 
For the analysis of all the secreted elements in cell culture medium (the so-called 
secretome, composed by both EVs and soluble proteins), heavy and medium-labeled 
melanoma cells were plated at 80% of confluence in 15cm dishes and washed three 
times with PBS and twice with serum-free DMEM to remove serum proteins. Then, 
cells were cultured in serum-free DMEM  for 20h in order to allow the release of a 
good amount of secreted protein maintaining cells viability over 95% (tested with 
MUSE® Count&Viability assay).  
Secretome analysis was performed in collaboration with Vittoria Matafora in the 
group. Briefly, conditioned media were centrifuged on VivaSpin 20 PES, 10000 
MWCO (Sartorius Stedim Biotech, Aubagne, France) that allowed both to concentrate 
soluble elements and to change DMEM with UA Buffer in order to perform MS 
analysis. Since soluble proteins are highly glycosylated, samples were treated with 
the endoglycosidase PNGaseF (New England Biolabs) to remove N-glycosidic groups 
before reduction and alkylation and a double digestion (Lys C/Trypsin) was performed 
to improve secretome coverage.  
7. Atomic Force Microscopy analysis  
Since EVs size is under the limit of detection of the optical microscopy, Atomic Force 
Microscopy (AFM), that have resolution at nanometric level, was used to obtain 
topographic images to have information about vesicles size maintaining vesicles 
integrity, as previously described {Sharma S., et al., 2011}. 
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Fresh EVs obtained by ultracentrifugation were resuspended in PBS, previously 
filtered with a 0.22µm filter in order to eliminate salt aggregates and other particles 
that could interfere with the analysis, and diluted in de-ionized water (from 1:10 to 
1:30 according to vesicles concentration from different donor cells).  
Samples were adsorbed to freshly cleaved mica sheets and then dried under a stream 
of nitrogen. EVs were then analyzed with a Nanowizard 3 AFM instrument (JPK 
Instruments, Berlin, Germany) under tapping mode and using silicon probes (ACTG 
probes; AppNano, Mountain View, CA, USA). Topographic height, amplitude, error 
and phase images were recorded simultaneously at 512x512 pixels (scan area: 25µm2) 
at a scan-rate of 0.8Hz.  
The measurements of EVs size was done analyzing the topographic height of the 
acquired images using a macro in FIJI/ImageJ Software in collaboration with Stefano 
Freddi at MolMed (IEO Milan). 
The measurement of EVs size was repeated in at least 3 biological replicates per 
sample in order to have a statistical significance of the results. Statistical analysis 
was performed with Prism GraphPad Software. 
8. Wound-Healing assay 
A Wound-Healing (WH) assay was performed to analyze the collective motility of 
primary and metastatic melanoma cells. 
3x104 WM115 or WM266.4 cells were carefully resuspended in 70µL of DMEM and 
plated into each chamber of a Culture-Insert 2 Well (Ibidi GmbH, Planegg, Germany), 
that allows the formation of a defined 500µm cell free gap in different biological 
replicates and different cell lines. The inserts were removed after 48 hours, when a 
uniform cells monolayer was formed, and wound closure was followed for 24 hours in 
live-imaging using an ORCA-AG camera (6.45µm pixel size; Hamamatsu, 
Sunayamacho, Japan) on an Olympus IX81 automatic microscope (Olympus, Tokyo, 
Japan) equipped with an environmental microscope incubator that maintained a 
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constant temperature of 37°C and a constant perfusion of 5% CO2 during the whole 
experiment. Cells pictures were acquired every 5 minutes by differential interference 
contrast imaging using a 10X objective (binning 2). For IGR39 and IGR37 cell lines, 
wounds were done manually by scratching the cells monolayer in a 6 well plate with a 
p200 tip because these cells do not move when seeded in Culture-Insert chambers. 
Data analysis was performed in collaboration with Emanuele Martini of the Imaging 
Technological Development Unit in the Institute using a custom MatLab and 
FIJI/Image J Software as previously described {Malinverno C., et al., 2017}. Wound 
closure values correspond to average slopes of linear equations derived from the 
analyses of the area (µm2) covered by the cells during the time. 
The WH assay was repeated in at least 3 biological replicates in order to have a 
statistical significance of the results. 
9. Gelatin Degradation Assay 
Fluorescent-labeled gelatin was prepared with Alexa Fluor®594 Protein Labeling Kit 
(Thermo Fisher Scientific) according to manufacturer instruction. 
The assay was carried out as previously described {Artym V.V., et al., 2009} with the 
following modifications. Autoclaved glass coverslips were washed once in 70% 
Ethanol, three times in sterile PBS and finally in sterile H2O to remove salt 
aggregates from PBS. Then, air-dried coverslips were coated with fluorescent-labeled 
gelatin (final concentration: 2mg/mL) and fixed with 0.5% ice-cold glutaraldehyde in 
PBS at 4°C for 15 minutes. After three washes in PBS, coverslips were incubated for 3 
minutes at room temperature with 5mg/mL Sodium Borohydride in PBS to reduce 
aldheydic groups, washed and sterilized again with 70% Ethanol and finally quenched 
in complete DMEM for 1h at 37°C. 
105 WM115 or WM266.4 cells were seeded on fluorescent gelatin coated coverslips 
transferred in 6wells and fixed with 4% parafolmaldheyde 9 or 12 hours after their 
adhesion; these time points were chosen as the best condition to allow invadopodia 
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formation before cells start to move. After the permeabilization in 0.25% TritonX-100 
in PBS on ice, actin structures and nuclei in the cells were stained by 1h incubation of 
FITC-Phalloydin (1:50 in PBS) and 5 minutes incubation with DAPI (1:5000 in PBS) 
respectively, then coverslips were mounted in mowiol solution and images were 
captured using a wide-field Olympus BX51 Upright microscope. 
10. Proteostat® aggresome detection assay 
In order to detect intracellular amyloids in primary and metastatic melanoma cells, 
Proteostat® Aggresome Detection Kit (Enzo Life Sciences, Farmingdale, NY, USA) 
was used according to manufacturer’s instructions. 
Briefly, 1.6x105 WM115 or WM266.4 cells were plated in 6 wells and allowed to 
adhere on 0.5% gelatin-coated glass coverslips. After 24 hours, cells were fixed with 
4% paraformaldehyde for 10 minutes, and permeabilized on ice with 0.25% Triton-
X100 and then incubated with Proteostat® reagent (1:2000 dilution) for 1 hour 
followed by  DAPI nuclear staining for 5 minutes, at room temperature. Coverslips 
were mounted in a 20% glycerol solution to avoid mechanical deformation of the 
sample and images were captured using a Leica inverted SP2 microscope with a laser 
scanning confocal system. 
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RESULTS 
1.Primary tumor and metastasis derived melanoma cells release qualitative 
and quantitative different Extracellular Vesicles  
1.1 Metastasis and primary tumor derived cell lines have the same shape and 
proliferation rate 
Advanced melanoma is among the most aggressive human cancers whose survival 
rate dramatically decreases once the tumor has metastasized {Miller A.J. and Mihm 
M.C. Jr, 2006}. Melanoma cells produce a large quantity of exosomes in comparison to 
normal melanocytes {Dror S., et al., 2016} and several studies have shown that the 
plasma of melanoma patients contains increased amounts of exosomes compared to 
plasma of healthy individuals {Logozzi M., et al., 2009}. However, a comparative 
proteomic characterization of the exosomes secreted by isogenic melanoma cell lines to 
address different contribution to the pre-metastatic niche establishment in metastatic 
versus primary tumor melanoma cells has never been performed. 
As model of primary tumor and metastatic melanoma, we choose the isogenic cell 
lines WM115 (primary tumor)/WM266.4 (skin metastasis), and IGR39 (primary 
tumor)/IGR37 (lymph node metastasis). Despite the fact that these cells pairs share 
the same karyotype, their aspect and their proliferation rate is very different. More in 
detail, both metastatic cells (WM266.4 and IGR37) have a spindle-like shape (Figure 
10A) and grow faster than primary tumor cells (WM115 and IGR 39) (Figure 10B).   
57 
 
 
Figure 10: Metastasis and Primary Tumor isogenic melanoma cell lines show the same aspect and proliferation rate.  
A)   Metastasis derived cells WM266.4 and IGR37 are small and show a spindle-like shape while primary tumor derived 
WM115 and IGR39 cells are bigger and show epithelial-like shape. 
B) Metastatic cells have higher proliferation rate when compared to primary tumor cells. The graph is referred to 
WM266.4/WM115 cells pairs as example 
1.2 Ultracentrifugation of conditioned media results in enrichment of Extracellular 
Vesicles 
So far, the term “exosomes” is often referred to an heterogeneous population of 
vesicles isolated through several techniques without any demonstration of their 
intracellular origin into multivesicular bodies (as discussed in the introduction, 
section 2.1) {Tkach M. and Théry C., 2016}. For this reason, we refer to Extracellular 
Vesicles (EVs) as the population of vesicles obtained following the canonical vesicles 
enrichment from conditioned media based on serial centrifugation {Théry C., et al., 
2006}.  
Isogenic melanoma cells were plated at 50% of confluence and, one day after plating, 
the medium was replaced with EVs-depleted DMEM. Conditioned media were then 
collected after 48 hours, when cells reached about 90% of confluency. No significant 
impairment in cell viability was observed by Methyl-Thiazol-Tetrazolium (MTT) assay 
when cells were cultured in EVs-depleted DMEM. Moreover, both erythrosine 
incorporation and MUSE®Count&Viability measurements resulted in >95% cells 
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viability, indicating that the presence of apoptotic bodies in the cells conditioned 
medium is irrelevant for the purpose of the EVs study (Figure 11). 
 
Figure 11: Viability of isogenic melanoma cells is maintained in EVs-depleted DMEM.  
A) MTT assay demonstrates that no significant impairment in cells viability can be observed when comparing EVs-
depleted DMEM (UC DMEM) and control medium (DMEM).  
B) MUSE®Count&Viability Assay shows that isogenic melanoma cells are able to duplicate after 48 hours in EVs-
depleted DMEM maintaining their viability above 95%. 
The quality of vesicles enrichment was assessed by Western Blot (WB) analysis 
evaluating the enrichment of well-known EVs-associated proteins (TSG101, ALIX, 
CD9, CD63, and CD81) and the absence of other cellular compartment-markers, 
following the guidelines published by Lötvall et al.{Lötvall J., et al., 2014} (Figure 12). 
 
Figure 12: The ultracentrifuged pellet is enriched in EVs and is not contaminated by organelles coming from other 
cellular compartments.  
A) EVs specific proteins TSG101, ALIX, CD81 and CD9 are enriched in the pellet (EVs) when compared to the Total Cell 
Lysate (TCL).  
B) Markers of Golgi Apparatus (Golgin 97), Nucleus (Lamin A/C and Histone H3) and Endoplasmic Reticulum (Calnexin) 
are enriched in TCL respect to EVs.  
The panel shows results obtained with WM266.4 cells and is indicative of all the four isogenic melanoma cell lines. 
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Considering that EVs size is under the limit of detection of optical imaging, we used 
nanometer-resolved Atomic Force Microscopy (AFM) to obtain topographic images 
maintaining vesicles integrity. The diameter of EVs was calculated with ImageJ 
Software as previously described {Sharma S., et al., 2011}. Our analysis showed that 
the mean size of enriched vesicles is 60nm in diameter, consistent with the presence 
of exosomes (Figure 13, A). These data confirmed previous measurement by 
Nanosight analysis, that revealed the presence of a distinct vesicles population with 
an average size of 75nm (Figure 13, B). 
.  
Figure 13: EVs size in the ultracentrifuged pellet is consistent with exosomes size.  
A) AFM analysis on EVs demonstrated that the mean EVs diameter is 60 nm.  
B) Nanosight analysis on EVs showed enrichment in a population with 75nm of diameter. 
Finally, to better differentiate between vesicles and protein aggregates that could 
precipitate together during the ultracentrifugation step, we optimize a fractionation of 
the EVs pellet on a discontinuous iodixanol gradient. For both primary tumor and 
metastatic cell lines, we enriched EVs in a density between 1.08 and 1.11 g/mL of 
iodixanol, which is the one reported in literature for melanoma exosomes {Sung B.H., 
et al., 2015} (Figure 14). 
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Figure 14: Ultracentrifuged pellet are enriched in melanoma exosomes.  
WB analysis on isolated EVs fractions demonstrates an enrichment of EVs proteins ALIX, TSG101, CD9 and CD81 in a 
density range between 1.08 and 1.11 g/mL both in WM115 primary tumor cells (Panel A) and in WM266.4 metastatic 
cells (Panel B). 
1.3 Primary tumor cells release more and bigger EVs respect to metastatic cells 
Providing that the extracellular environment is expected to contain qualitative and 
quantitative differences depending on the tumor progression state {Muralindharan-
Chari V., et al., 2010}, we used AFM imaging and FIJI/ImageJ Software to count the 
number of vesicles released by the same number of donor cells and to measure their 
size. 
For both WM115/WM266.4 and IGR39/IGR37 couples, we found that primary tumor 
cells release a larger number of vesicles with respect to metastatic ones (Figure 15, A 
and B). Moreover, we observed that the area of EVs released by primary tumor cells 
was bigger when compared to the area of EVs released by metastatic cells (Figure 15, 
C), indicating that primary tumor and metastatic cells could secrete different 
population of EVs. 
61 
 
 
Figure 15: EVs from primary tumor cells are larger in number and size than EVs released by metastatic cells.  
A) Images of topographic height of the EVs released by the four melanoma cell lines.  
B) Statistical analysis of the number of EVs per field demonstrates that for both isogenic melanoma cells pairs primary 
tumor cells release more EVs than metastatic cells.  
C) Statistical analysis of the EVs area (expressed in nm*nm) demonstrates that for both isogenic melanoma cells pairs 
primary tumor cells release bigger EVs than metastatic cells.   
1.4 Deep quantitative proteomics on melanoma EVs  
1.4.1 The majority of the identified proteins belong to primary tumor derived EVs 
We performed a deep quantitative proteomics analysis on EVs enriched from the same 
number of isogenic melanoma cells. We took advantage of the SILAC approach, 
labeling cells with heavy- and medium aminoacids, to measure the relative 
quantitation of each protein and to discriminate contamination from FBS proteins. 
The latter ones, being naturally light-labeled, could be excluded from the analysis by 
selecting only the heavy and medium-labeled aminoacids. 
As reported in the graph in figure 16A, we observed an increased amount of proteins 
coming from the primary tumor vs metastatic cells, and this observation was also 
validated by WB (Figure 16). 
62 
 
 
Figure 16: The majority of identified proteins belong to primary tumor EVs.  
A)  Ratio distribution of quantified proteins in primary tumor (WM115) vs metastatic (WM266.4) isogenic melanoma 
cells derived EVs shows that the majority of the proteins belongs to primary tumor derived EVs, that are medium-
labeled. 
B)  WB analysis validates the proteomics analysis both at the global proteome level (Ponceau) and following EVs 
enriched proteins expression (ALIX, TSG101). 
This result confirmed what we have previously observed by AFM analysis, where we 
noticed that primary tumor released EVs are bigger and more abundant with respect 
to metastatic EVs (Figure 15).  
1.4.2 EVs protein content is different between primary tumor and metastatic cells 
With deep quantitative proteomics, we were able to identify and quantify more than 
700 proteins in EVs released from WM cells and close to 1000 proteins in EVs 
released by IGR cells. Since about 350 proteins were shared between the two isogenic 
melanoma cells pairs, we looked at the normalized ratio of those proteins in order to 
identify candidates that can be considered markers of primary tumor-derived or 
metastasis-derived EVs. In particular, we focused on proteins that were significantly 
regulated (p value <0.05) in both WM and IGR EVs. We noticed that the majority of 
the proteins significantly enriched in EVs released by metastatic cells belongs to 
metabolic pathways or have a function in the Extracellular Matrix (ECM) 
organization. This  observation can explain the fact that the EVs pellet enriched from 
metastatic cells is sticky and hard to be re-dissolved in PBS, in accordance with the 
physical characteristics of the ECM components. On the contrary, primary tumor 
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derived EVs are enriched in proteins related to signaling pathways and cell migration 
(Table 5). 
 
Table 5: Proteins significantly regulated in metastasis-derived or primary tumor-derived EVs.  
Proteins up-regulated in EVs secreted by metastatic cells belong to pathways highlighted in red, while proteins up-
regulated in EVs secreted by primary tumor cells belong to pathways highlighted in green. 
1.4.3 Isogenic primary tumor and metastatic melanoma cells have different 
secretomes, suggesting an invasive vs a proliferative behavior  
Since the extracellular environment is expected to contain qualitative and 
quantitative differences between primary tumor and metastatic cells, we decided to 
use deep quantitative proteomics to analyze the isogenic melanoma cells secretome. 
We refer to secretome as the sample obtained after the concentration of the whole cell 
culture supernatant, containing both EVs and soluble secreted factors.  
The study of the entire secretome together with the EVs proteome allowed us to have 
a complete overlook of the proteins differentially secreted by isogenic primary tumor 
and metastatic melanoma cells, providing better indications of the cells behavior. 
Moreover,  since the secretome samples contains EVs, the results obtained with this 
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analysis validated what we observed by deep quantitative proteomics on EVs, 
indicating candidates that can be considered markers secreted by primary tumor or 
metastatic melanoma cells.  
As we did for EVs deep quantitative proteomics, we used heavy- and medium-labelled 
aminoacids to achieve relative quantitation of each protein. We plated the cells in 
FBS-depleted media to eliminate FBS proteins, that could impair the identification of 
proteins coming from the cells. Moreover, as a large number of proteins in the 
secretory pathway are N-Glycosylated {Aebi M., 2013}, to improve secretome coverage 
we decided to use the endoglycosidase PNGaseF to remove N-glycosidic groups from 
the proteins before the reduction and alkylation steps, thus allowing the digestion of 
highly glycosylated proteins.  
We identified and quantified more than 2000 proteins in the secretome of both 
isogenic melanoma cells pairs, and around 200 of them were differentially secreted 
(FDR <0.05) in primary tumor vs metastatic cells.  
In particular, both WM115 and IGR39 cells secretome was enriched in Matrix 
Metalloproteinases (MMPs), that contribute to ECM remodeling and vascular 
disruption trough ventral actin-rich membrane protrusions called invadopodia. The 
ability of tumor cells to form invadopodia directly correlates with their capacity to 
invade the local stroma and its associated vascular components {Martin K.H., et al., 
2012}. Therefore, we used gelatin degradation assay to visualize invadopodia-
mediated ECM degradation of cells by fluorescence microscopy, demonstrating that 
primary tumor cells form a higher number of invadopodia than metastatic cells 
(Figure 17). This finding suggests that primary tumor cells have an invasive 
phenotype, having the ability to degrade ECM to pass through the basement 
membrane and the walls of the circulatory and lymphatic systems. 
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Figure 17: Primary tumor cells show invasive behavior.  
A) 20X images of fluorescent-gelatin coated coverslips show that primary tumor cells are able to degrade fluorescent 
gelatin more than metastatic cells (time point: 9 hours). 
B) 40X magnification on a WM115 cell showing gelatin degradation by invadopodia: the black dots inside the cell in the 
gelatin channel correspond to the brighter dots in the phalloidin channel, used to label actin. 
On the contrary, WM266.4 and IGR37 cells secretome is enriched in proteins involved 
in ECM deposition, fibril deposition and cell adhesion molecules. Since the deposition, 
remodeling and signaling of ECM components influences the final outgrowth of 
macrometastases {Venning F.A., et al., 2015}, we hypothesize that metastatic cells 
have a proliferative behavior but further assays are necessary to validate this 
hypothesis. Moreover, lipid transporters such as Apolipoprotein E (APOE) and 
proteins belonging to the vesicles trafficking pathway, in particular melanosomal 
proteins, are significantly enriched in the secretome of metastatic cells (Figure 18). 
By combining the deep quantitative proteomics results obtained on EVs proteome, 
total cell proteome (see paragraph 3) and secretome, we decided to focus our following 
studies on APOE, Fibronectin (FN) and Wingless-related integration site family 
member 5A (WNT5A), highlighted in the Table 5 and in Figure 18. 
66 
 
 
Figure 18:  Summary of the proteomics results on EVs proteome, isogenic melanoma cells secretome and proteome. 
Left: The majority of the proteins significantly enriched in metastatic melanoma cells derived EVs are involved in 
metabolic pathways and extracellular matrix deposition, while primary tumor cells derived EVs are enriched in proteins 
involved in cell adhesion and in signaling pathways. Fibronectin (FN) , Apolipoprotein E (APOE) and WNT5A are the most 
significantly regulated proteins in metastatic and primary tumor cells derived EVs, respectively (better described in 
Table 5). 
Middle: Matrix Metalloproteinase 1 (MMP1) is significantly enriched in the secretome of primary tumor cells. On the 
contrary, the proteins significantly enriched in the secretome of metastatic melanoma cells belong to the collagens 
family (COL14A1, COL9A1, COL22A1) or are melanosomal proteins (RAB32, TYRP1). Of note, PMEL and APOE are 
significantly enriched in the secretome of metastatic melanoma cells. 
Right:  The graph represent the pathways significantly up-regulated in the proteome of isogenic primary tumor and 
metastatic melanoma cells (better described in in section 3). Among proteins of the vesicles trafficking pathway, 
RAB27A and its known effectors are highlighted in the table. 
2. Fibronectin and WNT5A are EVs-associated proteins, while APOE is mainly 
secreted as soluble factor 
2.1 Fibronectin is the major component of metastasis derived EVs 
ECM proteins were significantly enriched in metastatic cells derived EVs (Table 5).  
In particular, Fibronectin (FN) was found as the major component of WM266.4 EVs, 
and its specific EVs enrichment was sustained by the observation that this protein is 
not significantly enriched in metastatic cells proteome and secretome, suggesting that 
this protein could have an important role in metastatic cells derived EVs (Figure 19). 
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Figure 19: Fibronectin is enriched in metastatic cells secreted EVs.  
A) WB analysis to validate that Fibronectin is the most abundant protein in WM 266.4 EVs.  
B) Fibronectin enrichment is not significant in WM266.4 proteome and secretome.  
  Significantly enriched proteins (p value <0.05) are highlighted in red and are distributed outside of the dotted lines. 
To investigate the role of EVs-associated FN, we optimized a discontinuous iodixanol 
gradient for EVs fractionation. When applied to metastatic cells derived EVs, this 
approach resulted in FN enrichment in two different fractions, suggesting that it may 
be present in two different form: one soluble and another EVs-associated (Figure 20).  
 
Figure 20: Fibronectin is enriched at higher densities in WM266.4 respect WM115 samples.  
WB analysis demonstrates that, after the fractionation of EVs pellets on iodixanol gradient, fibronectin secreted by 
WM266.4 cells is enriched mainly at higher iodixanol densities. TSG101 is used as control for EVs banding densities.  
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The dual behavior of FN, that is both soluble and EVs-associated, is still under 
investigation. We reasoned that the EVs-associated FN could regulate the directional 
cell movement through tissues, as it was described by Sung and colleagues in 
fibrosarcoma-derived exosomes {Sung B.H., et al., 2015}.  
2.2 WNT5A is enriched in primary tumor secreted EVs 
The quantitative proteomics analysis revealed that WNT5A is one of the more 
significantly enriched proteins in primary tumor-released EVs (FDR <0.05). Since this 
protein is known to be secreted as soluble factor and its presence in melanoma 
exosomes has hardly been described, we validated its EVs-association by WB analysis 
after the fractionation on iodixanol gradient (Figure 21, A). Moreover, for both 
primary tumor and metastatic melanoma cell lines, we demonstrated that WNT5A is 
mainly enriched in EVs pellet rather than in the EVs-depleted-soluble factors-
containing sample (named soluble factors) obtained by concentrating the supernatant 
of the 100000g ultracentrifugation step (Figure 21, B). 
 
Figure 21: WNT5A is enriched in primary tumor EVs.  
A) The fractionation of EVs pellet secreted by IGR39 cells demonstrates the presence of WNT5A protein in the same 
fraction of EVs (CD81 was used as control of EVs banding density).  
B) The enrichment of WNT5A protein is higher in EVs than in the Total Cell Lysate and in the soluble factors containing 
sample. Images were cut to display only significant lanes (Loading: 30µg of each sample). 
It was reported that WNT5A overexpression in melanoma cells leads to an increased 
motility and invasion {Weeraratna A.T., et al., 2002}; for this reason, we hypothesized 
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that the delivery of WNT5A inside EVs might determine its horizontal transfer to 
neighboring cells to allow melanoma progression. 
2.3 APOE is mainly secreted as soluble factor in metastatic melanoma cells 
By combining the proteomics results on EVs and secretome in WM115/WM266.4 and 
IGR39/IGR37 cells, we found APOE as abundant component of metastatic 
microenvironment, being significantly enriched (FDR <0.05) both in EVs and in the 
secretome (Figure 22, A). However, differently from WNT5A, we observed the 
majority of the secreted APOE in the soluble factors sample (Figure 22, B) even if the 
fractionation of EVs pellet on iodixanol gradient demonstrated that this protein is 
enriched also in metastatic melanoma EVs (Figure 22, C). 
 
Figure 22: APOE is secreted as soluble factor by metastatic melanoma cells.  
A) APOE is significantly enriched both in metastatic melanoma cells secreted EVs and in metastatic melanoma cells 
secretome. Significant proteins (FDR<0.05) are highlighted in red outside the dotted lines.  
B) The enrichment of APOE protein is higher in the soluble factors containing sample than in the Total Cell Lysate and in 
the EVs. Images were cut to display only significant lanes (Loading: 30µg of each sample).  
C) The fractionation of EVs pellet secreted by WM266.4 cells demonstrates the presence of APOE in the same fraction 
of EVs (CD81 was used as control of EVs banding density). 
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Membrane-bound APOE in exosomes has been shown to regulate Premelanosome 
Protein (PMEL) amyloid fibrils loading it into vesicles during melanogenesis in 
normal melanocytes {Bissig C., et al., 2016}. For this reason, we are still investigating 
whether specific APOE sorting to EVs in metastasis versus primary tumor cells can 
help metastatic progression. In particular, we tested if higher levels of APOE in 
metastatic melanoma cells correlate with higher PMEL fibril deposition and if this 
process is mediated by vesicles secretion. To this aim, we started preliminary assays 
using Proteostat® Aggresome Detection Kit to visualize protein aggregates inside the 
cells. Our results demonstrate that in metastatic cells there is an accumulation of the 
Proteostat reagent in dotted structures, suggesting the presence of protein aggregates 
not only inside but also outside metastatic melanoma cells. This result confirmed 
what we observed by AFM analysis on metastatic melanoma EVs (Figure 23). 
Co-localization assays with PMEL, APOE and known vesicles enriched proteins and a 
screening of APOE isoforms are needed to demonstrate that these structures can be 
considered as amyloid plaques precursors. 
 
Figure 23: Proteostat reagent accumulates in dots inside and outside metastatic melanoma cells.  
Confocal images of WM266.4 cells labeled with Proteostat aggresome detection reagent demonstrate that Proteostat 
accumulates in dot structures (white arrows) both inside (upper image) and outside (lower image) metastatic 
melanoma cells. The aggregates outside metastatic melanoma cells can be the same structures that surround 
metastatic cells secreted EVs visualized by AFM (right image, white arrows). 
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3. Deep quantitative proteomics on isogenic melanoma cell lines  
3.1 Method development  
3.1.1 Peptide fractionation increases protein quantitation accuracy 
One of the purposes of our study was to dissect how the cells proteome can sustain 
metastatic progression. To better understand the differences in protein expression 
between primary tumor and metastatic cells, we used isogenic melanoma cells pairs, 
that share the same karyotype but show different phenotypes (Figure 10). 
To dissect the pathways that can induce metastatic progression, we optimized the 
deep quantitative proteomics protocol published by Kulak et al. as described in 
Materials and Method section (Figure 9). In particular, to prevent sample loss, cells 
were lysed in strong denaturing conditions and proteins were alkylated, reduced and 
digested in the same lysis buffer. To achieve a robust quantitative result, we coupled 
the canonical SILAC-based approach with Strong Cationic Exchange (SCX) peptide 
fractionation. Indeed, SCX fractionation allowed us to obtain a considerable number 
of peptides that eluted only in one of the five fractions in which the digested sample 
was split (Figure 24). This approach not only allowed us to increase the number of 
identified proteins but also improves protein quantitation accuracy, having more 
peptides that can be used to quantify the same protein. 
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Figure 24: Peptides fractionation increases protein quantitation accuracy. 
Distribution of peptides among the five SCX fractions. Red squares indicate the number of peptides eluted exclusively in 
one specific fraction, demonstrating the efficacy of the fractionation protocol.  
3.1.2 Deep quantitative proteomics method is reproducible and can be used to 
compare different samples 
As quality control for quantitative proteomics analysis, we followed the expression of 
reported melanoma progression antigen in metastatic versus primary tumor cells, 
according to the literature (Table 6). In particular, in metastatic cells we observed 
increased levels of MITF, Tyrosynase and Melanotrasferrin, which are critical master 
regulators of melanocytes development. Moreover, we found the overexpression of the 
oncofetal/cancer testis antigens of the melanoma-associated antigens (MAGE) family, 
which are normally expressed in testis or in placenta and increase their expression 
after cancer onset. Finally, Nestin levels were increased in metastatic versus primary 
tumor cells, as it is reported to significantly correlate with advanced stage of the 
disease{Hodi F.S., 2006}. On the contrary, Microtubule Associated Protein MAP2 was 
overexpressed in primary tumor cells, as it is frequently abundant in melanocytic nevi 
respect to metastatic cells {Maddodi N. and Setaluri V., 2010}. In these cells, we also 
observed the loss of Beta Catenin, associated with aggressive melanoma behavior 
{Bachmann I.M., et al., 2005}. Finally, primary tumor cells have higher levels of 
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CDK4, that leads to increased cells proliferation and resistance to BRAF inhibition in 
V600E mutated melanoma cells {Smalley K.S. et al., 2008}. 
Protein name Gene name 
Metastasis/Primary tumor 
Log2 Ratio 
Microphthalmia-associated transcription factor MITF 3,157577344 
Tyrosinase TYR 2,961771479 
Melanotransferrin MFI2 1,025524968 
Nestin NES 0,863304159 
Melanoma-associated antigen C2 MAGEC2 3,211572959 
Melanoma-associated antigen 6 MAGEA6 2,784964567 
Melanoma-associated antigen 10 MAGEA10 1,876133814 
Melanoma-associated antigen 3 MAGEA3 1,171399003 
   
Cyclin-dependent kinase 4 CDK4 -0,207211267 
Catenin beta-1 CTNNB1 -0,827051715 
Microtubule-associated protein 2 MAP2 -1,433934999 
Table 6: List of known melanoma progression markers used as quality control for proteomics analysis. 
The correlation of Log2 ratios between biological replicates demonstrates that our 
proteomics method is highly reproducible (Figure 25).  
 
Figure 25: Deep quantitative proteomics method is reproducible.  
Pearson correlation to demonstrate the reproducibility among two different biological replicates. 
For both isogenic melanoma cells pairs used in this study, we identified and 
quantified more than 6000 proteins, and around 200 proteins were significantly 
regulated (FDR <0.05), demonstrating that the deep quantitative proteomics method 
we optimized is accurate and not cell type specific (Figure 26).  
74 
 
 
Figure 26: Deep quantitative proteomics can be used to compare different samples. 
Proteins distribution according to their intensity and Log2 ratios is similar between WM115/WM266.4 and IGR39/IGR37 
cells. The number of quantified and significant regulated proteins is similar between the two samples. Significantly 
regulated proteins are highlighted in red (p value <0.05) and in green (FDR<0.05).   
3.2 Primary and metastatic isogenic melanoma cells show differences in their 
proteome  
Clustering regulated proteins in pathways according to EnrichR (Gene Ontology: 
Biological Process), we observed that both WM266.4 and IGR37 metastatic cells up-
regulate proteins involved in glucose and fatty acids metabolism, indicating that these 
cells need height ATP production. Moreover, our analysis shows the up-regulation of 
proteins belonging to the vesicles trafficking pathway, which includes both 
extracellular vesicles secretion and intracellular vesicles trafficking. On the opposite, 
WM115 and IGR39 primary melanoma cells are enriched in proteins regulating 
adhesion and intracellular signaling pathways (Figure 27).   
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Figure 27: Primary tumor and metastatic melanoma cells from different origin up-regulate similar pathways.  
Schematic representation of the up-regulated pathways in primary tumor and metastatic melanoma cells. The bars 
represent the numbers of proteins in each pathway. Pathways shared between WM266.4 and IGR37 are highlighted in 
red, while pathways shared among WM115 and IGR39 cells are highlighted in green. 
3.3 EVs proteome reflect the cells proteome but the secretion of the proteins in EVs is 
specifically regulated 
By comparing the results obtained by deep quantitative proteomics analysis on cells 
proteome and EVs proteome, we found that 65% and 83% of identified proteins in EVs 
proteome was in common with the identified proteins in WM cells and IGR cells 
proteome respectively (Figure 28, A). Moreover, proteins such as WNT5A are enriched 
in EVs respect to the cells proteome but maintain their ratio between primary tumor 
and metastatic samples (Figure 28, B). This result indicates that the EVs proteome 
can reflect the cells proteome and can thus be used to identify cancer type-specific 
biomarker, as recently hypothesized by Hurwitz and colleagues {Hurwitz S.N., et al., 
2016}. However, we found proteins specifically enriched in EVs that were not 
identified by proteomics analysis on the total cell lysate because their expression level 
inside the cells was too low, as in the case of EVs specific proteins (Figure 28, B). For 
this reason, the correlation between the normalized ratios of significantly regulated 
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proteins in EVs proteome and cells proteome is very low (Figure 28, C), suggesting 
that the secretion of proteins in EVs is highly regulated. 
 
Figure 28: The secretion of proteins in EVs is regulated.  
A) Venn diagrams show that the majority of the identified proteins in EVs are in common with the cells proteome (Venn 
diagrams were done with Venny2.1.0 {Oliveros J.C., 2007-2015}).  
B) Left: WB analysis demonstrates that WNT5A is enriched in EVs and maintain higher levels in WM115 respect to 
WM266.4 both in cellular and in vesicular proteome; Right: EVs enriched proteins ALIX, CD81 and CD9 are too low 
abundant in the TCL to be detected by WB analysis (Loading: 30µg of each lysate). 
C) The low  R
2
 value demonstrates a low Pearson correlation between significantly regulated proteins in EVs and cells 
proteome. 
3.4 RAB27A is up-regulated in metastasis vs primary tumor 
In order to understand if and how the proteome of cancer cells can sustain metastatic 
progression, we performed deep quantitative proteomics analysis on isogenic primary 
tumor and metastatic melanoma cell lines. We identify specifically enriched proteins 
and we clustered them in pathways (Figure 27). Of note, in metastatic cells we 
observed an up-regulation of the vesicles trafficking pathway, that included a 
significant increase of the Ras-Related protein Rab-27A (RAB27A), a member of the 
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RAB GTPase family, and of its known effectors (Table 7). These proteins are involved 
in melanosome transport and secretion in normal melanocytes and are required for 
both granules maturation and granules docking at the immunological synapses 
{Soldati T. and Schliwa M., 2006}. 
Protein Name Gene Name 
WM266.4/WM115 
Log2 Ratio 
IGR39/IGR37 
Log2 Ratio 
Ras-related protein RAB27A RAB27A 2.093624 4.466504 
Melanophilin MLPH 2.201719 2.201719 
Unconventional myosin-Va MYO5A 1.141185 2.954031 
Syntaxin-binding protein 1 STXBP1 1.338558 2.914434 
Synaptotagmin-like protein 4 SYTL4 0.978171 0.190721 
Table 7: List of RAB27A and its known effectors significantly enriched in metastatic melanoma cells proteome. 
We validated by WB RAB27A increased expression in metastatic vs primary tumor 
cells in both WM266.4 and IGR37 cells. Furthermore, we confirmed RAB27A 
expression also in 6 non-isogenic primary tumor and metastatic melanoma cell lines, 
suggesting that this protein might be important for metastasis progression (Figure 
29, A-B). Moreover, we observed a close to 10-fold increase of RAB27A expression in 
IGR37 with respect to WM266.4 cells (Figure 29, C), suggesting an increased 
melanosomes secretion in these cells, as demonstrated by the high pigmentation of 
IGR37 cells (Figure 29, D).  
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Figure 29: RAB27A is overexpressed in metastatic melanoma cells.  
A) WB analysis of isogenic melanoma cell lines WM115/WM266.4 and IGR39/IGR37 reveals high RAB27A protein levels 
in metastasis versus primary tumor cells.  
B)  RAB27A overexpression in metastatic melanoma cells is confirmed also in non-isogenic melanoma cell lines.  
C)  Densitometric analysis of RAB27A protein levels in isogenic melanoma cell lines.  
D)  IGR37 cells are highly pigmented, consistently with the high levels of RAB27A expression. 
4. RAB27A Knock Down affects metastatic melanoma cells clonogenic ability 
and motility and impairs EVs release 
In our quantitative proteomics analysis, we observed an overexpression of RAB27A in 
metastasis derived melanoma cell lines compared to their isogenic primary tumor-
derived cells. A correlation between high RAB27A mRNA levels and exosomal protein 
recovery has been previously reported in melanoma cells {Peinado H., et al., 2012} 
but, in contrast to what was previously described, we could not detect an increased 
exosomes production in metastatic cells, despite their high levels of RAB27A 
expression (Figure 16). For this reason, we hypothesized that in metastatic cells the 
secretion of a different population of EVs (such as melanosomes) could be 
predominant and we performed RAB27A KD to investigate if this phenomenon is 
controlled by RAB27A and its effectors. 
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To test the role of RAB27A in EVs secretion, we used lentiviral infection to stably KD 
RAB27A in metastasis derived WM266.4 and IGR37 cells. 
4.1 RAB27A KD affects IGR37 cells pigmentation and conformation  
In KD cells, we observed that the pigmentation of IGR37 cells was clearly impaired, 
indicating that this protein is involved in melanosomes trafficking (Figure 30, A). 
Moreover, IGR37 cells, instead of the usual spindle-like shape conformation 
preferentially clustered in a round-shape conformation (Figure 30, B), while no 
difference in cell shape was observed in WM266.4 cells upon RAB27A KD (Figure 30, 
C). 
 
Figure 30: RAB27A KD affects IGR37 cells pigmentation and conformation  
A) IGR37 KD cells lose their pigmentation (left); WB analysis shows the efficiency  of KD (right) in IGR37.  
B) IGR37 RAB27A-KD cells cluster together and show round-shape conformation (left picture) that is typical of dividing 
cells (middle picture).  
C) No differences in shape are observed in WM266.4 KD cells in respect to the scramble (left); WB analysis shows the 
reduced level of RAB27A upon KD (right) in WM266.4. 
80 
 
4.2 RAB27A-KD metastatic melanoma cells have increased clonogenic ability 
4.2.1 RAB27A KD increases the number of colonies formed by metastatic melanoma 
cells 
IGR37 cells assume rounded shape as soon as they detach from the plate to divide 
(Figure 30, B). Thus, we hypothesize that RAB27A could have an impact not only on 
vesicles secretion but also on cells proliferation. We set up a colony formation assay to 
test the ability of isogenic melanoma cell lines to undergo unlimited division, forming 
colonies from individual cells. 
We demonstrated that, after 10 days, primary tumor cells form more colonies than 
metastatic cells (Figure 31, A). Furthermore, knocking down RAB27A increases the 
number of colonies formed by metastatic melanoma cells, even if it does not restore 
completely the condition of primary tumor cells (Figure 31, B). We can therefore 
conclude that RAB27A expression reduces the clonogenic ability of metastatic 
melanoma cells. In order to better elucidate this phenomenon, we are investigating a 
correlation with EVs secretion. 
 
Figure 31: RAB27A KD affects the clonogenic ability of metastatic melanoma cells.  
A) In both isogenic melanoma cell pairs, primary tumor cells formed more colonies than metastatic cells.  
B) After RAB27A KD, the number of colonies formed by metastatic cells is increased. 
C) Statistical analysis of the number of colonies demonstrates that RAB27A KD significantly increases metastatic cells 
clonogenic ability 
81 
 
4.2.2 EVs secreted by wild type metastatic melanoma cells impair the clonogenic 
ability of RAB27A-KD cells 
Given the established role of RAB27A in EVs secretion {Ostrowski M., et al., 2010} 
and since we observed high colony formation in the presence of low levels of RAB27A 
expression, we tested if EVs or other secreted soluble factors could influence 
metastatic melanoma cells clonogenic ability. To perform this analysis, we set the 
protocol described in Materials and Methods (Figure 6). 
We observed that EVs enriched from WT metastatic melanoma cells are able to 
significantly reduce the number of colonies at the same levels of WT cells. This 
phenomenon does not occur in the presence of EVs-depleted secreted factors. 
Moreover, RAB27A-KD cells derived soluble factors do not promote colonies formation 
in WM266.4-WT cells (Figure 32). This result suggests the presence of a RAB27A-
independent vesicles population that could affect the clonogenic ability of metastatic 
melanoma cells. 
 
Figure 32: EVs secreted by WT cells impair RAB27A-KD cells clonogenic ability.  
The number of colonies formed by RAB27A-KD cells is significantly impaired when these cells are treated for 6 hours 
with EVs coming from WM266.4-WT (Scramble) cells but not with the corresponding soluble factors (left). Neither EVs 
nor soluble factors secreted by RAB27A-KD cells are able to modulate WT cells clonogenic ability (right), but the number 
of colonies formed by these cells is too low to perform a reliable statistical analysis. 
NT: Non-Treated control. 
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However, treating WT cells with EVs secreted by RAB27A-KD cells resulted in no 
increase in colonies possibly because the number of colonies generated by WT cells is 
too low to see an effect. To overcome this problem we will perform the same assay 
increasing both the number of starting cells and the duration of the experiment. 
4.3 RAB27A KD reduces both EVs number and EVs size 
Our preliminary analyses demonstrate that RAB27A KD impacts cells behavior and 
that this fact might be related to EVs secretion. To better dissect the mechanism that 
regulate this phenomenon, we looked for qualitative and quantitative differences in 
EVs secretion after RAB27A KD. We performed AFM analysis on EVs secreted by the 
same number of RAB27A-WT and RAB27A-KD WM266.4 and IGR37 cells.  
In both cases, we not only counted less vesicles after RAB27A KD, as reported in 
literature, but we also observed a significant reduction of the EVs area in RAB27A-
KD. These results suggest that suggesting that RAB27A could participate in the 
regulation of a specific vesicles subpopulation, affecting in particular the biggest one 
(Figure 33).  
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Figure 33: RAB27A KD reduces both EVs number and EVs size  
A) AFM images show that EVs coming from both RAB27A-KD WM266.4 and RAB27A-KD IGR37 cells are less and smaller 
when compared to the WT counterpart.  
B) Statistical analysis shows that both the reduction of EVs number and size are significant. Only the images taken from 
the same EVs dilution were considered as biological replicates for statistical analysis. 
4.4 Proteomics analysis of RAB27A-KD cells secreted vesicles 
Given the differences in EVs number and size observed by AFM analysis, we 
performed SILAC-based deep quantitative proteomics analysis as previously reported 
(section 1.4) to identify proteins that can be considered markers of RAB27A-
dependent EVs subpopulation. 
EVs were enriched from the supernatant of the same number of either RAB27A-WT 
and RAB27A-KD metastatic melanoma cells, and four biological replicates were 
considered for the analysis because of the low amount of recovered vesicles.  
4.4.1 RAB27A KD affects the levels of specific EVs enriched proteins 
We focused our attention on those proteins whose enrichment was different between 
primary tumor and metastatic cells derived EVs, starting from the known EVs 
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enriched proteins. We observed that CD9 and CD81 levels are decreased after 
RAB27A KD, and we confirmed this result by WB analysis, in which samples were 
normalized on protein content and no more on donor cells number (Figure 34, A and 
B). To further corroborate our findings, we observed CD81 in IF performed on 
metastatic melanoma cells. When observed at the confocal microscopy, cells treated 
with siRNA targeting RAB27A show impaired CD81 expression at the plasma 
membrane (Figure 34, C).  
Finally, the same WB analysis showed that ALIX and CD63 seem to be increased in 
EVs after RAB27A KD (Figure 34, B), suggesting that CD81, ALIX and CD63 could be 
used as markers of RAB27A-dependent and RAB27A-independent EVs 
subpopulations, respectively.  
 
Figure 34: Not all the EVs enriched proteins decrease after RAB27A KD  
A) CD9 and CD81 Log2 Ratio shows that these proteins are decreased in EVs after RAB27A KD.  
B) WB analysis confirmed the decrease of CD81 and shows the increase of ALIX and CD63 proteins in WM266.4 RAB27A-
KD cells secreted EVs. Ponceau is shown to demonstrate the loading of the same amount of  total EVs proteins 
(Loading: 15µg). 
C) Immunofluorescence analysis on IGR37-WT (Scramble) and IGR37 RAB27A-KD cells shows decreased levels of CD81 
expression at the plasma membrane. 
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To test this hypothesis, we will sort CD9 and CD81 positive EVs and we will perform 
proteomics analysis to compare their proteome to the RAB27A-WT cells secreted EVs. 
This experiment will allow us to better define this specific vesicles population and to 
understand if these vesicles contain proteins that can be followed as markers of 
melanoma metastatic progression. 
4.4.2 RAB27A KD impairs the secretion of proteins related to ECM organization 
Proteins related to ECM organization, in particular Fibronectin, were found 
significantly enriched in metastatic cells derived EVs (Table 5). We observed that, 
after RAB27A KD, the level of these proteins in EVs is decreased (Table 8), possibly 
demonstrating a role of RAB27A in regulating the selective delivery of ECM proteins 
to EVs. 
Protein name  Gene name  
RAB27A-KD/RAB27A-WT 
Log
2
 Ratio 
Tenascin  TNC  -2,31691 
Fibronectin  FN1  -0,89898 
Collagen alpha-2(IV) chain  COL4A2  -1,22394 
Inter-alpha-trypsin inhibitor heavy chain H5  ITIH5  -0,88674 
Collagen alpha-1(I) chain  COL1A1 -0,61099 
Collagen triple helix repeat-containing protein 1  CTHRC1  -1,87065 
Collagen alpha-1(XXII) chain  COL22A1  -1,26925 
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3  PLOD3  -0,62027 
Thrombospondin-4  THBS4  -0,73975 
Collagen alpha-1(XII) chain  COL12A1  -0,34195 
Matrilin-2  MATN2  -3,41468 
Lactadherin  MFGE8  -1,40422 
Thrombospondin-1 THBS1 -1,16988 
Dystroglycan  DAG1  -1,02717 
Table 8: Proteins related to ECM organization decrease in EVs after RAB27A KD  
The Log2 Ratio of identified and quantified proteins related to ECM organization is reported. Proteins highlighted in red 
were found enriched in metastatic cells derived EVs. Among those, the ones in bold have a significant enrichment  
(p value <0.05) in metastasis derived EVs. 
4.4.3 WNT5A secretion in EVs is increased after RAB27A KD, while APOE does not 
change 
Through the combined analysis of the the proteomics results on EVs and secretome in 
WM115/WM266.4 and IGR39/IGR37 cells, we found WNT5A and APOE as abundant 
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components of primary tumor and metastatic microenvironment respectively. 
Moreover, we demonstrated that WNT5A is mainly enriched in primary tumor cells 
secreted EVs respect to their soluble factors. The opposite behavior was found for 
APOE is enriched in metastatic melanoma cells soluble factors, even if a little amount 
of this protein seems to be EVs-associated (Figures 21 and 22). 
After RAB27A KD, we observed an increase in EVs-associated WNT5A, that is typical 
of primary tumor EVs, while its levels in the Soluble Factors sample were unchanged. 
On the contrary, RAB27A KD does not affect the secretion of APOE both in vesicles 
and as soluble factor (Figure 35, A). This result suggests the possibility to use WNT5A 
as marker of the RAB27A-independent EVs subpopulation. Interestingly, we observed 
the same increase in WNT5A levels also in the proteome of RAB27A-KD metastatic 
cells (Figure 35, B).  To understand if RAB27A could interact with WNT5A to promote 
its turnover at the cellular level or if it does modulate WNT5A expression we will 
perform further experiments, starting with an immunoprecipitation of intracellular 
RAB27A to test its possible interaction to WNT5A or to proteins that could regulate 
cellular WNT5A expression.   
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Figure 35: WNT5A secretion in EVs is increased after RAB27A KD.  
A) WB analysis on the same amount of EVs lysates and soluble factor containing sample demonstrates the increase of 
WNT5A levels only in EVs after RAB27A KD, while both EVs-associated and soluble APOE remain unchanged. 
Ponceau staining is shown to demonstrate the loading of the same amount of sample in each lane (Loading: 15µg).  
B) WNT5A levels are increased in the total cell lysate after RAB27A KD, while APOE remains unchanged. 
4.5 RAB27A KD increases the motility of metastatic melanoma cells 
WNT5A was reported to promote directional cells movement both in physiological and 
pathological conditions in mouse and human cells {He F., et al., 2008; Bakker E.R., et 
al., 2013; Arabzadeh S., et al., 2016}. We observed that RAB27A KD increases the 
levels of cellular and EVs-associated WNT5A, thus we used Wound Healing (WH) 
assay to assess the effect of RAB27A KD on cells motility. Notably, we observed that 
RAB27A-KD cells close the wound earlier than WT cells (Figure 36, A). This result 
confirmed our hypothesis that the increase of WNT5A as consequence of RAB27A KD 
lead to higher cells motility. To test if EVs-associated WNT5A can act as an autocrine 
signal to affect melanoma cells motility, our future plan is to perform the same WH 
assay after the stimulation of metastatic cells with EVs and other secreted soluble 
factors released by either WT or RAB27A-KD cells.  
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Moreover, we used WH assay to analyze differences in cells motility between isogenic 
primary tumor and metastatic melanoma cells. For both the isogenic melanoma cells 
pairs, primary cells have higher motility if compared to metastatic cells (Figure 36, 
B), in accordance with the invasive phenotype that we hypothesized by combining 
secretome analysis and gelatin degradation assay. 
 
Figure 36: RAB27A KD increases the motility of metastatic melanoma cells  
A) Images of the wound at the beginning (0 hours) and at the moment of wound closure for WM266.4-WT (Scramble) or 
KD samples. RAB27A-KD cells close the wound faster than WT cells. 
B) Quantification and statistical analysis of the wound closure speed for each cell line. In both cases, primary tumor cells 
are faster than metastatic cells and RAB27A KD significantly increases metastatic cells wound closure speed. The 
speed is expressed in µm
2
/min as the software calculated the area covered by cells in every time frame. 
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DISCUSSION 
During metastasis formation, the secondary organs are selectively modified by the 
primary tumor through the Pre Metastatic Niche (PMN) establishment, an abnormal, 
tumor growth-favoring microenvironment devoid of cancer cells. The survival and 
proliferation of metastases is a consequence of PMN evolution, as the combined result 
of bone marrow derived cells recruitment, extracellular matrix remodeling and 
inflammation {Peinado H., et al., 2017}. Nonetheless it was demonstrated that a pre-
conditioned microenvironment is necessary to allow the outgrowth of cancer cells in 
the secondary organ {Kaplan R.N., et al., 2005}, the understanding of which 
characteristics distinguish the PMNs established in each organ is still matter of 
debate. Moreover, cancer cells that reach the PMNs before surgical removal of the 
primary tumor continue to secrete PMNs-promoting factors, that support the 
formation of further metastases. For this reason, targeting PMNs is highly desirable 
in cancer therapy to reduce or to prevent metastatic disease {Sceneay J., et al., 
2013}.  
Tumor derived secreted factors are key players in PMN establishment and facilitate 
organotropic metastasis {Hoshino A., et al., 2015}. Those factors include molecules 
directly secreted from the cell in the extracellular space (secreted factors) and 
Extracellular Vesicles (EVs), a heterogeneous population of vesicles constituted by a 
lipid bilayer and containing all of the known families of biomolecules (nucleic acids, 
lipids, proteins, metabolites) {Mittelbrunn M. and Sánchez-Madrid F., 2013}. Altough 
the gold standard procedure to enrich and characterize EVs subfamilies is still 
missing, the community refers to “exosomes” as the small-size vesicles (30-100 nm) 
originating in the endosomal compartment, and to “microvesicles” as the vesicles that 
originate by the budding from the plasma membrane and have a size comprised 
between 100 and 1000 nm. Tumor cells-derived EVs have been shown to contribute to 
PMN formation by the transfer of their cargo to stromal cells which populate PMNs 
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{Ratajczak J., et al., 2006}, that are reprogrammed towards a pro-metastatic and a 
pro-inflammatory phenotype in a cancer type and  pre-metastatic organ depending 
manner. Notably, EVs are stable, abundant and easy accessible in body fluids, 
becoming the most promising biomarkers for assessing the risk of tumor progression 
and metastasis. For this reason, a full characterization of secreted vesicles 
subpopulations and of their associated cargo is necessary to understand how EVs 
affect PMN formation. 
In this context, the aim of this project was to characterize the different secretion 
between isogenic primary tumor and metastatic melanoma cells. Indeed, we used a 
comparative proteomics analysis on cancer cells and on their secreted factors (both 
EVs and soluble secreted factors) to investigate how differences in primary tumor 
versus metastatic microenvironment affect the behavior of cancer cells. 
We focused our analysis on melanoma since it is among the most aggressive human 
cancers and its survival rate dramatically decreases once the tumor has metastasized 
{Miller A.J. and Mihm M.C. Jr, 2006}. Compared to normal melanocytes, melanoma 
cells produce a large quantity of exosomes, that can be detected in the plasma of 
melanoma patients {Peinado H., et al., 2012}.  So far, a comparative proteomic 
characterization of the exosomes secreted by isogenic melanoma cell lines to address 
different contribution to the PMN establishment in metastatic versus primary tumor 
melanoma cells has never been performed.  
To dissect the differences in the proteome of cells and of their secreted vesicles, we 
choose the isogenic cell lines WM115 (primary tumor)/WM266.4 (skin metastasis), 
and IGR39 (primary tumor)/IGR37 (lymph node metastasis). These cells share the 
same karyotype, thus allowing us to focus on differences in the proteomic content of 
cells and of their secreted vesicles. Despite originating from different organs, both 
metastatic cells have a spindle-like shape and grow faster than primaru tumor cells 
(Figure 10). The use of isogenic cells to compare the proteome of EVs secreted from 
primary tumor and metastatic cells has been already reported in literature. However, 
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the cancer cells used as “parental line” and injected in mice to induce metastasis from 
which the “metastatic line” was established were not necessarily isolated from the 
primary tumor, thus impairing the discovery of biomarkers for early-stage tumors 
{Maus R.L.G., et al., 2017}. For this reason, we started our study with commercially-
available cell lines that were isolated from the primary tumor and the metastasis of 
the same patient. This approach will also allow us to identify candidates that could be 
successively validated in EVs secreted by non-isogenic primary tumor and metastatic 
melanoma cells. 
Moreover, we chose cell lines with different BRAF mutation. Indeed, WM115 and 
WM266.4 cells have V600D BRAF mutation, while IGR39 and IGR37 cells have 
V600E BRAF mutation, most common in melanoma (source: Cancel Cell Line 
Encyclopedia). BRAF somatic missense mutations are characteristic of approximately 
half of all malignant melanoma {Davies H., et al., 2002}. The inhibition of mutated 
BRAF results in rapid regression of metastatic melanoma, even if the reactivation of 
MAPK pathways or alternative BRAF splicing are often able to induce resistance 
after the immediate antitumor effect {Monsma D.J., et al., 2015}, in a process that 
could depend on the increasing of cellular WNT5A {Anastas J.N., et al., 2014}. Given 
that the studies on the role of EVs in BRAF-inhibitors resistance are referred only to 
BRAFV600E mutations, we selected cells with different mutations of BRAF. This 
approach would help us in the future to understand if BRAF inhibitors alter the 
global EVs proteomic content in a BRAF mutation-dependent manner, in order to 
better understand which molecules contribute to the resistance after BRAF inhibitors 
treatment. 
In this study, we demonstrated for the first time that the EVs enriched by differential 
centrifugation from the conditioned media of isogenic primary tumor and metastatic 
cells are qualitatively and quantitatively different. Indeed, we observed an increased 
release of EVs from the primary tumor in comparison with metastatic cells. Moreover, 
the area of EVs released by primary tumor cells was bigger when compared to the 
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area of EVs released by metastatic cells (Figure 15). This phenomenon can influence 
the EVs cargo because the differences in size can be reflected in differences of 
molecules concentration inside the EVs. Of note, the size of EVs could also provide 
information about the metabolic state of the cells. Indeed, a large quantity of lipids is 
necessary to produce the external lipids bilayer of these big vesicles, but lipids 
synthesis is an energy-dependent process that require a highly active metabolic state 
to provide to the cells the energy needed to exploit all the physiological functions. 
To understand if the cargo of EVs reflects the qualitative and quantitative differences 
that we observed by AFM, we performed a SILAC-based deep quantitative proteomics 
analysis on EVs enriched from the same number of isogenic melanoma cells. We found 
an increased amount of proteins coming from the primary tumor vs the metastatic 
cells (Figure 16), consistent with the observation that EVs secreted from primary 
tumor are bigger in number and size than the ones released by metastatic cells.  
Furthermore, to have a complete overview of the extracellular factors differentially 
secreted by primary tumor and metastatic cells, we used SILAC-based deep 
quantitative proteomics to analyze the cells secretome, that is the sample obtained 
after the concentration of the whole cell culture supernatant, containing both EVs and 
soluble secreted factors. Since the secretome contains EVs, the results obtained with 
this analysis validated what we observed by deep quantitative proteomics on EVs, 
indicating candidates that can be considered markers secreted by primary tumor or 
metastatic melanoma cells. For what concern EVs, about 350 proteins were identified 
and quantified in common between the two isogenic melanoma cells pairs, and we 
noticed that the majority of the proteins significantly enriched in EVs released by 
metastatic cells (p<0.05) have a function in ECM organization (Table 5). This result is 
in accordance with the fact that BMDCs adhesion to PMN sites is promoted by the 
local increase of ECM deposition induced by EVs. Moreover, Fibronectin (FN) was 
found as the major component of WM266.4 EVs, and its specific EVs enrichment was 
sustained by the observation that this protein is not significantly enriched in 
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metastatic cells proteome and secretome (Figure 19). To better characterize the role of 
EVs associated FN, we optimized a discontinuous iodixanol gradient for EVs 
fractionation. We demonstrated that, in primary tumor cells-derived EVs, FN is 
enriched in the same fraction of known EVs protein, suggesting the association of this 
protein to the vesicles membrane, while in the metastatic cells-derived EVs FN is 
enriched at higher densities, suggesting that it may be mainly fibrillar (Figure 20). 
This phenomenon could be due to a higher FN secretion in metastatic cells EVs 
respect to primary tumor EVs and might have a biological function during metastatic 
progression. Indeed, a similar behavior of FN, both membrane-associated and 
fibrillar, was reported by Sung and colleagues in fibrosarcoma-derived exosomes, in 
which the EVs-associated FN regulated the directional cell movement through tissues 
in an integrins/FN interaction-dependent process {Sung B.H., et al., 2015}, and this 
mechanism could be the same used by primary tumor cells to start metastatization. 
Then, the enrichment of fibrillar FN on the surface of metastatic cells-derived EVs 
might facilitate the interaction of these vesicles with BMDCs in PMN, as it was 
reported for exosomes isolated from the serum of multiple myeloma patients 
{Purushothaman A., et al., 2016}.  
Moreover, we demonstrated that APOE secretion is predominant in metastatic 
melanoma cells. In accordance with its function of secreted lipid transporter {Mahley 
R.W. and Rall S.C.Jr, 2000}, we detected the majority of APOE in the EVs-depleted 
soluble factors sample (Figure 22). However, APOE specific enrichment at vesicular 
level (Figure 22) may reveal a so far not described function of this protein in 
metastatic melanoma EVs. Indeed, Bissig and colleagues demonstrated that, in 
normal melanocytes, the association of APOE to the membrane of vesicles regulates 
the clearance of PMEL amyloid fibrils {Bissig C., et al., 2016}. Furthermore, it was 
recently hypothesized that pigment cells eliminate immature amyloid fibrils through 
exosomes secretion {van Niel G., et al., 2015}. Since our preliminary analysis 
demonstrated the presence of protein aggregates outside metastatic melanoma cells 
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and since we observed that that EVs enriched from metastatic melanoma cells are 
surrounded by fibrillar structures (Figure 23), we hypothesize that the specific 
enrichment of APOE on EVs might mediate fibril deposition from metastatic cells. 
Finally, the quantitative proteomics analysis revealed that WNT5A is significantly 
enriched in primary tumor released EVs (FDR <0.05). This protein is known to be 
secreted as soluble factor, but very little is kown about WNT5A presence and function 
in EVs. We validated WNT5A as EVs’ cargo after EVs fractionation on iodixanol 
gradient, demonstrating that WNT5A is mainly enriched in EVs pellet rather than in 
the EVs-depleted-soluble factors both in primary tumor and metastatic melanoma cell 
lines (Figure 21). It has been reported that, in malignant melanoma cell lines, 
WNT5A up-regulation induces the release of exosomes containing pro-angiogenic and 
immunosuppressive factors, correlating with the formation of distant metastasis 
{Ekström E.J. et al., 2014}. Of note, no WNT5A gene amplification or rearrangement 
were found in WNT5A overexpressing cells {Weeraratna A.T., et al., 2002}, and for 
this reason it is reasonable to think that the levels of this protein inside the cell are 
modulated by other mechanisms, such as its uptake from EVs, and that this 
phenomenon might have a biological function. Indeed, it was reported that WNT5A 
overexpression in melanoma cells leads to an increased motility and invasion 
{Weeraratna A.T., et al., 2002}. Since primary tumor cells have higher levels of 
WNT5A expression compared to theit isogenic metastatic counterpart (Figure 21, B), 
we used Wound Healing (WH) assay to analyze differences in cells motility between 
isogenic primary tumor and metastatic melanoma cells. For both our isogenic couples, 
we observed that primary tumor cells motility was significantly higher than 
metastatic cells motility (Figure 36), in accordance with the idea that WNT5A 
promotes directional cells movement {He F., et al., 2008; Bakker E.R.M., et al., 2013; 
Arabzadeh S., et al., 2016}.  
To evaluate the specificity of the EVs proteome and to dissect how the cells proteome 
can sustain metastatic progression, we optimized the deep quantitative proteomics 
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protocol published by Kulak et al. to dissect the proteome of isogenic primary tumor 
and metastatic melanoma cell lines. Coupling the canonical SILAC-based approach 
with Strong Cationic Exchange peptide fractionation, we obtained a robust 
quantitative result. Indeed, a considerable number of peptides was detected only in 
one of the five fractions in which the digested sample was split (Figure 24), increasing 
the number of identified proteins and improving protein quantitation accuracy. 
Moreover, the quantitative method is accurate and not cell type specific, as we 
identified and quantified more than 6000 proteins for both isogenic melanoma cells 
pairs and around 200 proteins were significantly regulated (FDR <0.05) (Figure 26). 
Taken together, these findings lead to the conclusion that the deep quantitative 
proteomics protocol we developed is a useful tool to dissect the proteome of cell lines 
couples, opening the possibility to have an untargeted approach to identify changes in 
the entire proteome. 
By comparing the results obtained by deep quantitative proteomics analysis on cells 
proteome and on EVs proteome for both isogenic melanoma cell pairs, we 
demonstrated that a fraction of proteins was shared between the two samples, in 
accordance with the hypothesis that EVs can be used to identify cancer-specific 
biomarkers {Hurwitz S.N., et al., 2016}. Moreover, since those proteins have the same 
behavior in primary tumor vs metastatic sample both in EVs and in the total cells 
proteome, it is reasonable to think that specific molecules can be used as markers of 
metastatic progression in melanoma. However, the correlation between the 
normalized ratios of significantly regulated proteins in EVs proteome and cells 
proteome is very low, indicating that isogenic primary tumor and metastatic 
melanoma cells highly regulate both their cellular proteome and their EVs proteome 
(Figure 28). 
Looking at the pathways enhanced in metastatic cells, we found a significant up-
regulation of proteins belonging to the vesicles trafficking pathway, that include both 
extracellular secretion and intracellular trafficking. Among those, we observed a 
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significant increase of the RAB GTPase RAB27A and of its known effectors in 
WM266.4 and IGR37 metastatic cells (Table 7) and we validated its enhanced 
expression also in other 6 non-isogenic metastatic melanoma cell lines compared to 
primary tumor cell lines, suggesting that this protein can be important for metastasis 
progression (Figure 29).  
This observation is in contrast with our AFM and proteomics analyses, that 
demonstrate a higher EVs secretion by primary tumor cells, despite their low level of 
RAB27A expression. Indeed, RAB27A was reported to promote exosomes secretion in 
HeLa cells by mediating multivesicular endosomes docking at the plasma membrane 
{Ostrowski M., et al., 2010}. Moreover, in a panel of Sk-Mel melanoma cells series, 
Peinado and colleagues demonstrated that high levels of RAB27A mRNA positively 
correlate with metastatic potential and high recovery of exosomal proteins. On the 
opposite, they also showed that RAB27A KD reduce exosomal proteins recovery 
{Peinado H., et al., 2012}. Since RAB27A is involved in melanosome transport and 
secretion in normal melanocytes {Soldati T. and Schliwa M. 2006} and since we 
observed a high pigmentation in IGR37 cells (Figure 29), we hypothesized that, in 
metastatic cells, the secretion of a different population of EVs, such as melanosomes, 
could be predominant. 
To investigate if this phenomenon is controlled by RAB27A and its effectors, we 
performed RAB27A KD in metastatic cell lines. First of all, we observed an 
impairment of IGR37 cells pigmentation, in accordance with the involvement of this 
protein in melanosomes trafficking.  Moreover, IGR37 RAB27A-KD cells clustered in 
a round-shape conformation, that is the shape usually assumed by these cells as soon 
as they detach from the plate to duplicate (Figure 30). For this reason, we hypothesize 
that RAB27A expression could have an impact on cells growth, as its involvement to 
promote or to impair cells proliferation has been reported for glioma and gastric 
cancer cells, respectively {Wu X., et al., 2013 and Li Y., et al., 2017}. Having observed 
that metastatic cells grow faster than primary tumor cells (Figure 10), we set a colony 
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formation assay to test the ability of isogenic melanoma cell lines to undergo 
unlimited division, forming colonies from individual cells. We demonstrated that 
primary tumor cells have higher clonogenic ability than metastatic cells and that 
knocking down RAB27A increases the number of colonies formed by metastatic 
melanoma cells (Figure 31), suggesting that RAB27A has a negative effect on colony 
formation. Notably, our preliminary results demonstrated that EVs enriched from WT 
metastatic melanoma cells are able to significantly reduce the number of colonies 
formed by RAB27A-KD cells, suggesting that a RAB27A-independent vesicles 
population could improve or maintain the clonogenic ability of these cells. As further 
confirmation of this hypothesis, we observed that RAB27A-KD EVs-depleted soluble 
factors do not promote colonies formation in WM266.4-WT cells (Figure 32). 
So far, the idea that EVs act in a paracrine manner to maintain a stem cell-like 
phenotype was established with the observation that EVs released from embryonic 
stem cells sustained the maintenance of hematopoietic cell stemness and 
multipotency by delivering specific proteins and mRNA {Ratajczak J., et al., 2006}. 
Moreover, recent evidences explain the interplay between stem progenitors and their 
secreted vesicles in tumor progression {Nawaz M., et al., 2016}. The mechanisms by 
which cancer stem cell-derived EVs initiate and promote tumor progression are still 
uncertain, but with our study we have the first evidence that a specific subpopulation 
of EVs (that is, RAB27A-independent) has an important role in maintaining 
clonogenic ability, that is one particular characteristic of cancer stem cells.  
AFM analysis on EVs secreted by the same number of RAB27A-WT and RAB27A-KD 
melanoma cells supported the hypothesis of the presence of RAB27A-dependent and –
independent subpopulations. Indeed, we not only counted less vesicles after RAB27A 
KD, as reported in literature, but we also observed for the first time a significant 
reduction of the EVs area in RAB27A-KD sample, indicating that RAB27A is involved 
in particular in the secretion of bigger vesicles (Figure 33). 
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To identify proteins that could be considered markers of RAB27A-dependent EVs sub 
population, we performed SILAC-based deep quantitative proteomics analysis on EVs 
enriched from the supernatant of the same number of either RAB27A-WT and 
RAB27A-KD metastatic melanoma cells. Since it was shown that the distribution of 
the known EVs enriched proteins is not homogeneous among EVs sub populations 
{Kowal J., et al., 2016}, we started our analysis focusing on tetraspanins, observing 
that only CD9 and CD81 levels are decreased after RAB27A KD, while CD63 seems to 
be increased together with ALIX that is used to identify EVs even if it does not belong 
to tetraspanins family (Figure 33). This result is in accordance with the previous 
hypothesis that CD63-bearing EVs represent a sub population {Kowal J., et al., 2016} 
and suggests that CD9/CD81 and CD63/ALIX could be used as markers of RAB27A-
dependent and RAB27A-independent EVs subpopulations, respectively. Furthermore, 
EVs secreted by RAB27A-KD cells showed an increase in EVs-associated WNT5A, 
that is typical of primary tumor EVs, while the levels of its soluble form remain 
unchanged (Figure 35), suggesting the possibility to use WNT5A as auxiliary marker 
of the RAB27A-independent EVs subpopulation. To investigate if these EVs 
subpopulations have different secretion routes that can be affected by RAB27A KD, 
we followed the intracellular distribution of tetraspanins and preliminary results on 
IGR37-WT and IGR37 RAB27A-KD cells showed that RAB27A KD impairs CD81 
expression at the plasma membrane (Figure 28).  
Proteomics analysis demonstrated also that RAB27A KD impairs the expression of 
ECM proteins in metastatic cells secreted EVs (Table 8), suggesting a role of RAB27A 
in regulating the selective secretion of ECM-delivering EVs.  
Finally, WH assay showed that the motility of RAB27A-KD cells was higher than the 
one of WT cells (Figure 36). Since RAB27A-KD cells secrete EVs with higher WNT5A 
levels compared to WT cells, this finding supports our hypothesis that vesicular 
WNT5A can be horizontally transferred to increase cells motility trough the increase 
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of its cellular levels. Indeed, we observed that RAB27A KD increases the levels of 
cellular WNT5A (Figure 35).  
The role of RAB27A –independent EVs subpopulation in maintaining cells clonogenic 
ability and in promoting cells motility through WNT5A delivery needs further 
experiments to be assessed, but our preliminary results demonstrate that RAB27A –
independent EVs could possibly sustain cancer progression by paracrine stimulation 
of cancer cells and mediate tumor-PMN  communication by long-range activity. 
Future Plans 
1. Evaluation of ECM proteins association to EVs 
Considering that mass spectrometry analysis on isogenic cells’ secretome 
demonstrated the specific FN enrichment in WM266.4 EVs, that were isolated from 
skin, we want to further investigate if this mechanism is restricted to specific cell 
lines depending on their metastatic origin, reflecting the way that metastatic cells use 
to induce a tumor sustaining phenotype on secondary organs resident cells. To this 
aim, we will use MS analysis to quantify ECM proteins association to EVs in isogenic 
WM115/WM266.4 and IGR39/IGR37 cells, performing immunoaffinity EVs 
enrichment targeting tetraspanins as well-known EVs membrane proteins.  
Moreover, to demonstrate that RAB27A is involved in the secretion of ECM-enriched 
EVs, we will overexpress RAB27A in primary tumor cells and we will use MS analysis 
to evaluate the increase of ECM proteins in their EVs. 
Finally, to assess the different functions of EVs-associated FN in isogenic primary 
tumor and metastatic cell-derived EVs, we will perform directional motility assay in 
the presence of primary tumor derived EVs, bearing membrane-associated FN. We 
will then evaluate the different ability of primary tumor-derived or metastasis-
derived EVs to recruit BMDC to demonstrate the role of fibrillar fibronectin in 
mediating this event. 
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2. Characterization of the biological function of EVs-associated APOE 
We will overexpress APOE in WM115 and IGR39 cells to understand if its sorting to 
EVs could be affected by its higher expression at the cellular level. Furthermore, we 
will investigate if higher levels of APOE in metastatic melanoma cells correlate with 
higher PMEL fibril deposition, and if this process is mediated by vesicles secretion. To 
this aim, co-localization assays with PMEL in fibrils are needed to demonstrate that 
these structures can be considered as amyloid plaques precursors. Moreover, we will 
co-stain APOE and known EVs enriched proteins to demonstrate that fibril deposition 
is an EVs-mediated process that could protect metastatic cells, preventing them to be 
reached from external agents such as drugs. 
3. Characterization of the biological function of the EVs-associated WNT5A 
We will stably express GFP-WNT5A in primary tumor cells to track the protein inside 
the cells by live imaging and to follow its internalization into recipient cells after co-
culture assays or after EVs addition in recipient cells medium. To test if WNT5A is 
exposed on vesicles surface or it is just delivered inside the vesicles from donor to 
recipient cells, we will remove EVs surface proteins with proteinase K and we will 
look at the presence or absence of GFP signal in vesicles as readout for WNT5A 
removal. We hypothesize that the presence of WNT5A on vesicles surface would 
indicate the possibility that primary melanoma cells use EVs to activate the non-
canonical WNT signaling pathway in neighboring cells to promote survival and 
metastatization through PI3K/AKT signaling activation {Katoh M., 2017}. On the 
opposite, WNT5A delivery inside EVs could dock the protein to reach targets that are 
distant from cancer cells, such as the PMN in the secondary organ.  
To demonstrate the involvement of EVs-associated WNT5A in increasing cells 
motility, we will perform WH assay stimulating recipient cells with EVs carrying low 
levels of WNT5A. For this reason, we will establish WNT5A KD primary tumor cells, 
that will be used as donors for WNT5A-depleted vesicles with whom WT primary 
tumor cells will be stimulated before performing WH. 
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To understand if cellular WNT5A increase is due to vesicles uptake, we will measure 
the levels of this protein in metastatic cells, that have low WNT5A expression, after a 
stimulation with both primary tumor and RAB27A-KD cells derived EVs. Moreover, 
to exclude the hypothesis that RAB27A directly inhibit WNT5A expression, we will 
immunoprecipitate RAB27A both in primary tumor and metastatic melanoma cells to 
test its binding to WNT5A or to proteins that could regulate its cellular expression. 
We will also perform WH assay after the stimulation of metastatic cells with EVs and 
secreted soluble factors released by either WT or RAB27A-KD cells to test the 
possibility that RAB27A -dependent and -independent EVs subpopulations can act as 
a paracrine signal to affect melanoma cells motility, for example through WNT5A 
delivery. 
4. Investigation of the role of RAB27A-dependent EVs sub population 
We expect that RAB27A overexpression in primary tumor cells would impair their 
clonogenic ability promoting the secretion of EVs whose cargo would be similar to the 
one of metastatic cells derived EVs. The analysis of the EVs cargo will take into 
consideration not only the proteome but also the presence of mRNAs and miRNAs, to 
understand if these vesicles could modify the phenotype of neighboring cells by 
modulating their gene expression. 
Moreover, to understand if RAB27A-dependent vesicles contain proteins that can be 
followed as markers of metastatic progression in melanoma, we will sort CD9 and 
CD81 positive EVs and we will perform proteomics analysis to compare their 
proteome to the RAB27A-WT secreted EVs.  
To better characterize the role of EVs cargo proteins in inducing changes in recipient 
cells we will establish non-contact co-culture transwell system to mimic a long-range 
communication due to the continuous production of EVs and secreted proteins. SILAC 
will be used to define how secreted factors impact on recipient cells: heavy and 
medium-labeled recipient cells will be respectively exposed to melanoma donor cells 
and, after 8-16-24 hours of co-culture, cells will be lysed and analyzed by deep 
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quantitative proteomics. Proteins with a significant ratio will give us readout of the 
molecular pathways affected by the exposure to primary tumor or metastatic donor 
cells secreted factors and indicate how and if recipient cells are educated towards a 
pro-tumoral phenotype. 
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